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Background: In a previous trial we reported that the neuroprotective, anti-inflammatory antibiotic minocycline
lessened the negative symptoms of schizophrenia compared with placebo over 1 year. The BeneMin study
aimed to replicate this benefit and to determine whether or not there was associated preservation of grey
matter, reduction in circulating inflammatory cytokines and enhancement of cognition.
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Objectives: To determine the efficacy of minocycline on the negative symptoms of schizophrenia and the
mechanistic role of neuroprotective, anti-inflammatory and cognitive enhancing actions.
Methods: Two hundred and seven patients with a current research diagnosis of schizophrenia within 5 years
of onset were randomised by a permuted blocks algorithm to minocycline (300mg/day) or matching placebo
as an adjunct to their continuing treatment. The primary efficacy outcome variable was the negative symptom
subscale score from the Positive and Negative Syndrome Scales at 2, 6, 9 and 12 months. The primary
mechanistic (biomarker) variables were (1) medial prefrontal grey matter volume (GMV), (2) circulating
cytokine interleukin (IL) 6 concentration and (3) dorsolateral prefrontal cortex functional magnetic resonance
imaging (fMRI) activations during performance of the N-back task. Movement disorder, side effects and
treatment adherence were monitored throughout the study.
Results: Compared with placebo, the addition of minocycline had no effect on the severity of negative
symptoms [treatment effect difference –0.186, 95% confidence interval (CI) –1.225 to 0.854] across the
2-, 6-, 9- and 12-month follow-up visits. None of the mechanistic biomarkers was influenced by minocycline:
left GMV –91.2 (95% CI –303.8 to 121.4), IL-6 0.072 (95% CI –0.118 to 0.262) and N-back fMRI 0.66
(95% CI –1.53 to 0.20). There were no statistically significant treatment effects on any of the secondary
outcomes and no group differences at baseline. Most measures were stable over the 12 months. Twenty-five
out of the 29 serious adverse events were hospital admission for worsening psychiatric state, which affected
10 minocycline-treated participants and six placebo-treated participants.
Main outcome measures: The addition of minocycline to standard treatment had no benefit on the
symptoms of schizophrenia in this early phase sample. There was no evidence of a progressive neuropathic
or inflammatory process affecting GMV.
Limitations: Although recruitment to target was achieved on time, only 43% (n = 89) of the 207 randomised
patients completed 12 months of the study. However, 83% of those who started treatment remained on
it and were assessed over 6 months. By contrast, no follow-up data were available for the cognitive and
imaging markers in those who dropped out before the final 12-month assessments, and this reduced
the power to detect treatment effects on these mechanistic variables. Patients were not selected for the
presence of negative symptoms, and their initial overall psychopathology was, at most, moderate and,
therefore, less likely to show treatment effects.
Conclusions: The results of the study do not support the use of adjunctive minocycline for the treatment
of negative or other symptoms of schizophrenia within 2–5 years of onset. More secure evidence of central
inflammation is needed before further trials are conducted at other stages of psychosis.
Trial registration: Current Controlled Trials ISRCTN49141214.
Funding: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical
Research Council (MRC) and National Institute for Health Research partnership. The study was sponsored
by Greater Manchester Mental Health NHS Foundation Trust and supported by the UK Clinical Research
Network.
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Plain English summary
We have completed a clinical trial in 207 people who had received a diagnosis of schizophrenia inthe previous 5 years. These participants agreed to add a well-known antibiotic called minocycline
to their usual treatment for 1 year. The aim was to check previous evidence that minocycline may improve
symptoms of schizophrenia such as self-neglect, social withdrawal, apathy and unemployment (so-called
negative symptoms) that can develop and persist after treatment with current antipsychotic medication.
We also tested the idea that minocycline might work by supporting the functioning of brain cells, perhaps
through its anti-inflammatory actions.
Interested patients in early intervention and community services in 11 UK NHS trusts were taken through
the study by local research teams. Neither the participants nor the researchers knew who was taking
real minocycline and who was taking matching dummy (placebo) capsules. Clinical interviews and
questionnaires were used to follow any changes in psychotic and negative symptoms as well as general
health and social functioning over the 12 months of treatment. Brain functioning was assessed using
magnetic resonance imaging scans and performance tests. Molecules associated with inflammation called
cytokines were measured in blood samples.
When we decoded the results after the last participant had completed the study, we found that there
were no differences in any of the clinical measures between those who had taken minocycline and those
who had taken the placebo capsules. Further analyses are under way, but we found that there was no
general tendency to worsening of symptoms, brain function or inflammation over the 12 months of
standard care and that taking minocycline provided no additional benefit. The results make it unlikely that
there is an inflammatory process that gives rise to negative symptoms in recent schizophrenia that is
modifiable by minocycline. We cannot exclude the possibility that minocycline would benefit a more
severely ill group who have not responded to standard treatments.
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Scientific summary
Background
Even when treatment is adequate, people with established schizophrenia often have an impaired quality of life,
experiencing social isolation, self-neglect, unemployment and reduced activities of daily living. Three factors
fairly consistently relate to impaired social functioning: cognitive impairment [intelligence quotient (including
lower IQ)], the duration of untreated psychosis (DUP) and negative symptoms. A prolonged DUP is associated
with the development of marked negative symptoms. Such findings suggest that active psychosis may reflect a
neuropathic process that results in negative symptoms and, thus, in impaired quality of life. This hypothesis is
reinforced by evidence of progressive loss of grey matter volume (GMV) in the early 1–5 years of psychosis.
This has led to interest in directly targeting neuroprotection in the development of early treatments to
prevent negative symptoms and cognitive decline and thus to improve social function and quality of life.
Preclinical reports of the neuroprotective effects of the antibiotic minocycline led us to conduct a clinical trial
in early schizophrenia comparing minocycline and matching placebo, added to treatment as usual (TAU).
After 1 year, improvement in negative symptoms, but not in positive symptoms, was significantly greater
after taking minocycline than after taking placebo. The Efficacy and Mechanism Evaluation programme
BeneMin study aimed to replicate the initial clinical benefit and to determine whether or not any benefit
could be attributed to neuroprotective, anti-inflammatory or cognitive-enhancing effects of the drug.
Objectives
The study strategy was to use the recently developed PsyGrid infrastructure for UK-wide clinical and
imaging research in first-episode psychosis to achieve the following objectives: (1) to determine whether
negative symptoms can be lessened or prevented by minocycline treatment initiated early in the course
of schizophrenia and (2) to collect biomarker data to test hypotheses about how minocycline improves
negative symptoms. To meet these objectives, we designed the BeneMin study, a 1-year multicentre,
double-blind randomised placebo-controlled trial of minocycline versus placebo, added to standard
antipsychotic drug (APD), for patients within 5 years of a diagnosis of a schizophrenia-related psychosis.
The clinical trial treatment was oral minocycline, 300 mg daily for 12 months, or matching placebo capsules.
Based on power calculations, we aimed to recruit 225 participants to achieve 85 completers for each
treatment group.
The primary efficacy prediction and the mechanistic hypotheses were:
l Minocycline minimises later negative symptoms when administered during the acute phase of
early psychosis.
l Minocycline reduces or prevents the negative symptoms of schizophrenia by:
¢ reducing the loss of grey matter associated with early psychosis
¢ interfering with inflammatory cytokine production
¢ acting on glutamate systems to improve negative symptoms and cognitive function.
The primary clinical outcome was the negative symptom subscale score of the Positive and Negative
Syndrome Scale (PANSS). The mechanistic biomarker variables were (1) change in medial prefrontal GMV
from magnetic resonance imaging (MRI) scans, (2) circulating cytokine concentrations and (3) working
memory performance and functional MRI (fMRI) activations in the frontal cortex. We aimed to relate these
measures to changes in negative symptom severity and quality of life. Other clinical ratings were made at all
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visits, at months 0 (randomisation), 2, 6, 9 and 12, to establish the time course of any benefit. Mechanistic
imaging and cognitive measures were made at the first and last visits, and cytokines were measured in
blood samples taken at 0, 2, 6 and 12 months. Participants were followed up 3 months after completing
the trial phase with all efficacy assessments to determine whether or not any treatment effects had been
sustained.
Methods
The study population was people aged 16–35 years who met the Diagnostics and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV), criteria for schizophrenia or schizophreniform or schizo-affective
psychosis, as assessed by the clinical team and confirmed by the Mini-International Neuropsychiatric
Interview, which was administered by a member of the research team. Other inclusion criteria included
being within 5 years of the onset of psychotic symptoms; the current presence of at least one of four
items from the PANSS positive symptom subscale, indicating a continuing episode; being under the care
of an early intervention, community or inpatient adult service; and having the ability to provide informed
consent, including being fluent in English and having an IQ of > 70. Patients could not take part if, in the
investigators’ opinion, substance misuse could interfere with the study or if their behaviour involved risk of
violence or of self-harm, or if they had coexisting medical disorders revealed at clinical examination or by
laboratory blood screening tests.
The primary clinical outcome variable was the negative symptom subscale score on the PANSS. Raters were
trained and tested on the Standardised Clinical Interview for PANSS ratings (SCI-PANSS). The PANSS total
and positive symptom subscales scores were secondary symptomatic efficacy variables. Functional outcome
was assessed by the Global Assessment of Functioning (GAF) scale from the DSM-IV and the self-rated
Social Functioning Scale (SFS). Cognitive outcomes included digit-symbol processing speed task, list learning,
verbal fluency and IQ measures. Standard clinical measures of APD side effects covered extrapyramidal
symptoms (EPS) such as parkinsonism, akathisia and tardive dyskinesias as well as non-neurological APD side
effects. Spontaneously reported side effects were recorded. Treatment-emergent depressive symptoms and
body mass index (BMI) were monitored.
The three primary biomarker outcome variables tested the three mechanistic hypotheses: (1) preservation
of prefrontal GMV, (2) decreased circulating cytokine interleukin (IL) 6 and high-sensitive C-reactive protein
(hsCRP) concentrations, and (3) increased dorsolateral prefrontal cortex blood oxygen level-dependent
(BOLD) response and performance during the N-back task.
Patients were randomised by the automated Open Clinical Data Management System to receive minocycline
increasing from 200mg to 300 mg/day or matching placebo capsules after they had completed safety and
all research assessments. Efficacy measures were repeated at 2, 6 and 9 months, and all safety and research
assessments were repeated at 12 months, the end of the trial medication phase. All assessments were
repeated at 15 months, which was 3 months after stopping trial medication, to determine whether or not
any treatment effects required continuing treatment with minocycline.
Results
A total of 207 patients were randomised in the trial: 104 to placebo and 103 to minocycline. A total of
75% of the participants remained in the study at 6 months and 60% remained at 12 months. There were
no statistically significant treatment effects on any of the primary or secondary clinical or mechanistic
outcomes (Table a). There was no significant tendency to loss of grey matter or increasing negative
symptoms. Patients were not selected for the presence of negative symptoms and their initial ratings
corresponded to a mild to moderate degree of severity, which improved minimally over the 12-month
treatment phase by < 3 points. Circulating hsCRP and IL-6 cytokine concentrations did not change from
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baseline to 6 or 12 months and were unaffected by allocation to minocycline. Treatment effects were not
modified in participants with baseline hsCRP and IL-6 concentrations above or below the median.
The pattern of usual drug treatment was unaffected by treatment allocation, and there were no effects on
the low rates of EPS or other antipsychotic side effects including the small increase in BMI.
Adherence to trial medication was assessed using self-ratings of attitude to trial medication at every visit.
The number reporting a high level of medication adherence (defined by a score of 6 or 7 on the 7-point
treatment adherence scale) declined from approximately 85% at 2 months to 65% at 6 months and
onwards. This was broadly in line with the rate of non-detectable minocycline measured in an ad hoc assay
of minocycline in blood samples taken for cytokines at 6 and 12 months. An exploratory analysis did not
reveal significant effects of minocycline in those patients reporting high medication adherence or in those
with detectable plasma minocycline.
TABLE a Summary of best estimates of treatment effect
Primary outcome Estimate Standard error p-value 95% confidence interval
Negative symptomsa –0.19 0.53 0.73 –1.23 to 0.85
Clinical outcomes
Positive symptomsa –0.19 0.47 0.68 –1.12 to 0.73
Total symptoms (PANSS)a –0.58 1.62 0.72 –3.75 to 2.59
CDSSa –0.06 0.40 0.88 –0.84 to 0.72
GAF scorea 2.71 2.15 0.21 –1.57 to 6.98
SFS withdrawalb –0.24 0.40 0.55 –1.33 to 0.55
SFS relationsb –0.02 0.27 0.94 –0.55 to 0.51
SFS independence-performanceb –0.78 0.89 0.38 –2.53 to 0.97
SFS recreationb –0.91 0.89 0.30 –2.65 to 0.82
SFS prosocialb 0.19 1.24 0.88 –2.25 to 2.62
SFS independence-competentb –0.49 0.67 0.46 –1.79 to 0.81
SFS employmentb –0.12 0.43 0.78 –0.95 to 0.71
Processing speedc –2.14 2.26 0.35 –6.63 to 2.35
Current IQc –0.56 1.53 0.72 –3.59 to 2.47
Weightc 2.71 2.15 0.21 –1.57 to 6.98
Biomarker outcomes
GMV (left)c –0.09 0.11 0.40 –0.30 to 0.12
GMV (right)c –0.07 0.07 0.34 –0.21 to 0.08
N-back 1 + 2 > 0-back (%BOLD)c –0.66 0.43 0.13 –1.53 to 0.20
IL-6b 0.07 0.10 0.46 –0.12 to 0.26
hsCRPb 1.72 1.60 0.28 –1.42 to 4.85
CDSS, Calgary Depression Scale for Schizophrenia.
a 2-, 6-, 9- and 12-month follow-up.
b 6- and 12-month follow-up.
c 12-month follow-up.
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Conclusions
The evidence from this study suggests that the administration of minocycline treatment for 1 year, in addition
to standard treatment, early in the course of schizophrenia has neither a beneficial nor an adverse effect on
clinical outcome. There were no differences in any of the primary or secondary efficacy or mechanistic outcome
measures after 2, 6, 9 or 12 months between the minocycline- and placebo- treated groups. There was no
evidence of an active process of grey matter loss, cognitive impairment or systemic inflammation that could
have been engaged by minocycline. The findings were consistent across centres and unrelated to measures of
treatment adherence. The results indicate that minocycline is not an effective adjunct to standard treatment of
recent-onset schizophrenia. They also suggest that persistent inflammation and changes in grey matter are not
a general or persistent feature in the first 5 years of psychosis.
Trial registration
This trial is registered as ISRCTN49141214.
Funding
This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research
Council and National Institute for Health Research partnership. The study was sponsored by Manchester
Mental Health and Social Care Trust and supported by the UK Clinical Research Network.
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Chapter 1 Background and objectives
Negative symptoms of schizophrenia
Patients with chronic schizophrenia have an impaired quality of life, experiencing social isolation, self-neglect,
unemployment and reduced activities of daily living, despite current treatments. Symptoms are broadly
grouped into positive and negative. The negative symptoms reflect the absence or diminution of normal
behaviours and functions, and include emotional and social withdrawal, anhedonia, lack of drive and
deficiencies in emotional responsiveness. Negative symptoms persist and, along with cognitive impairment
and the duration of untreated psychosis (DUP), they fairly consistently relate to impaired social functioning.1
Findings such as the correlation between DUP and negative symptoms suggest that active psychosis may
reflect a neuropathic process that results in negative symptoms and thus in impaired quality of life. This has
led to interest in directly targeting neuroprotection in early treatment to prevent the development of or
alleviate negative symptoms and cognitive decline and thus improve social function and quality of life.
Although positive and disorganised symptoms usually respond to drug treatment, no antipsychotic drug
(APD) treatment is unequivocally effective for negative symptoms.
Previous studies of minocycline and symptoms of schizophrenia
The Stanley Medical Research Institute funded two double-blind, randomised, placebo-controlled studies2,3
of the putative neuroprotective agent minocycline for the negative symptoms of schizophrenia. A two-centre
study in Brazil and Pakistan2,4 was supervised by the University of Manchester. A total of 94 people with
schizophrenia who were on stable medication completed 12 months of add-on treatment with placebo or
minocycline. Minocycline-treated patients showed an overall greater improvement in their total Positive and
Negative Syndrome Scale (PANSS) score (p = 0.03). This was driven by the improvement in negative syndrome
scores (p = 0.007; Cohen’s d = 0.54); the improvement in positive symptom ratings was smaller and only
trend significant (p = 0.06). In a subset of patients, ratings made at 6 months were available, and treatment
effects were apparent at that time. These data also suggest that improvement in negative symptoms continues
to 12 months but that improvement in positive symptoms is maximal at 6 months. Although improvement
in positive symptoms was small overall, it was very marked in four patients in the Brazil arm of the study,
suggesting that the effect of minocycline may be significantly heterogeneous. A marked acute antipsychotic
effect of minocycline has been reported in treatment-resistant patients.5 A second randomised controlled
trial (RCT) was carried out in Tel Aviv3 in 70 relapsed patients. After stabilisation on a second-generation APD,
the patients were randomised to placebo or minocycline in a 1 : 2 ratio. Significant treatment effects on
negative but not on positive symptoms were detectable at the first rating at 3 months. No other trials were
registered on US or UK databases prior to BeneMin.
Mechanism of action of minocycline: anti-inflammatory and
neuroprotective
Minocycline has been shown to have neuroprotective properties in preclinical models of several
neurodegenerative diseases.6,7 Preliminary clinical trials suggested that stroke8 and Parkinson’s disease9 may
be helped by minocycline but that amyotrophic lateral sclerosis (ALS) and Huntington’s disease are not.10,11
Neuronal cell numbers are not reduced in post-mortem brain studies in schizophrenia, which points rather
to loss of neuronal branching and possible loss of the astroglial and oligodendroglial cells that support
neuronal function.12 Furthermore, there is a good case for antecedent developmental abnormalities.13
Nevertheless, subtle loss of grey matter in brain imaging studies certainly occurs, and this continues with
transition to psychosis and during the early course of schizophrenia. Lieberman et al.14 reported loss of
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grey matter in magnetic resonance imaging (MRI) scans in patients treated in their first year of illness,
and this was also reported by Cahn et al.15 over 5 years. In the latter study, the brain changes predicted
poor functional outcome and DUP predicted the grey matter changes.16 The demonstration that minocycline
lessens grey matter loss and its association with improved negative symptoms would galvanise action on
neuroprotection as a major therapeutic target in schizophrenia.
Minocycline has multiple anti-inflammatory and anti-apoptotic properties; for example, it decreases production
of cytokines and inducible nitric oxide synthase, and inhibits microglial activation.17 The case for inflammatory
mechanisms in schizophrenia had strengthened prior to BeneMin. For example, immune gene variants are
associated with psychosis risk, and a meta-analysis18 of many studies of circulating cytokine concentrations had
reported medium effect sizes (≈0.5) for IL-1 receptor antagonist (IL-1RA), IL-2R and IL-6. Some post-mortem
brain studies and a recent positron emission tomography (PET) imaging study have reported evidence of
microglial activation in schizophrenia.19,20 Although stroke and other neurological disorders are associated
with increased circulating cytokines, it remains uncertain whether or not the cytokines originate from the
brain. We proposed to use MRI structural sequences that are sensitive to brain inflammation and to determine
whether or not group differences relate to circulating cytokines.
Minocycline, glutamate and schizophrenia
Impaired N-methyl-d-aspartate (NMDA) glutamate receptor function has long been implicated in the
pathogenesis of schizophrenia. Drugs such as phencyclidine and ketamine block NMDA function and
reproduce predominantly the negative symptoms of schizophrenia in healthy volunteers.21 They cause
dysfunctional glutamate release, which can exert neurotoxic effects.22 Atypical APDs lessen their behavioural
effects and, remarkably, so does minocycline.23 Furthermore, we recently found evidence that a single
pretreatment of anaesthetised rats with minocycline caused a highly significant block of ketamine’s
desynchronising effects on cortical electrophysiology (Professor J Gigg, University of Manchester, 2014,
personal communication). Thus, minocycline could improve negative symptoms by reversing a disease-related
impairment of NMDA function that may directly underlie negative symptoms or cause them via a toxic effect
on neuronal branching or glial support cells. We used cognitive performance, in the absence of a measure of
glutamate function, to detect a pharmacological action rather than, or in addition to, neuroprotective effects.
We aimed to determine whether the benefits of minocycline on negative symptoms were direct or were
mediated by an improvement in cognitive processes, as reflected by functional magnetic resonance imaging
(fMRI) during the N-back working memory task.
Rationale for the BeneMin study
The rationale of the study was to use proven scientific infrastructure to:
l conduct a multisite, double-blind, RCT to evaluate the effectiveness of minocycline in addition to
standard care, compared with standard care alone, in preventing the development or worsening of
negative symptoms of schizophrenia over 1 year if given early in the course of the illness
l understand how minocycline works.
The study built on the demonstrated proof of concept of the efficacy of minocycline on negative symptoms
in two placebo-controlled clinical trials24,25 in patients on stable APD treatment. Minocycline also lessened
weight gain in both RCTs and was well tolerated, with a good safety profile. The study aimed to evaluate
how rapidly minocycline works on negative symptoms in early (first 5 treated years) psychosis and whether
or not it is effective in reducing positive symptom; there are no placebo-controlled trials in acute psychosis.
Minocycline could therefore reduce the considerable side effect burden of APDs (e.g. weight gain, diabetes
mellitus and hyperlipidaemia) by reducing the dose of APDs necessary to improve psychosis and by
lessening drug-induced weight gain. A clinically important health gain was realistic given the effect size of
0.5 on negative symptoms in the two efficacy trials.
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Minocycline has a number of actions that could be relevant to its neuroprotective effects and to its beneficial
effects in schizophrenia. Therefore, validated biomarkers of potential disease mechanisms were built into
the trial design. The study thus aimed to test an entirely new scientific and clinical principle in the treatment
of psychosis, with broader implications for our understanding of the relationship between brain changes,
cognitive function and negative symptoms.
Most of the principal investigators collaborated on the Medical Research Council-funded PsyGrid e-science
project. PsyGrid constructed an information systems platform, recruited 960 first-episode psychosis patients
in 2 years and collected longitudinal clinical assessments that have been used in the power calculations for
this study. Patients were identified by research assistants (RAs) based in eight collaborating centres of the
Mental Health Research Network. The CSOs carried out assessments and transferred anonymised data via
their local computer portal of the Open Clinical Data Management System (OpenCDMS) secure project
management software. The proposed study used the same methods, including randomisation, and trial
management functions already deployed in other multisite trials. PsyGrid addressed the ethical and legal
issues involved in the secure and confidential research assessment of people in their first episode of psychosis.
Rationale and feasibility of multicentre imaging
Feasibility study
Large numbers of patients are needed to allow detection of subtle biological effects of psychiatric illness and
drug action on brain structure and function. Imaging studies conducted across multiple centres offer major
opportunities to bring patient recruitment into a manageable time frame. However, there are significant
operational and statistical challenges, notably the addition of between-centre variance. To address these
issues, the PsyGrid and NeuroPsyGrid25 consortia undertook a longitudinal calibration study in which
12 male volunteers were scanned at five centres under the same study protocol as we propose to use.
A voxel-based method of calculating statistical power for multicentre imaging studies was derived from these
data and has been used as the basis for power calculations herein.24 In addition, functional and structural
MRI data were modelled at each brain voxel to estimate the partitioning of variance between the main
effects of centre, subject, occasion and within-occasion order, as well as interactions of centre-by-occasion,
subject-by-occasion and centre-by-subject.
Between-centre variance was limited to around 10% of the total. The main effect of subject was the largest
variance partition for structural MRI (70–80%), and error (unexplained) variance was the largest for functional
MRI (> 80%). Moreover, subject-by-centre interactions were generally 1–2% of the total variance. Therefore,
there are no insurmountable obstacles to using MRI as an outcome variable in multicentre trials, and including
a factor for centre in analysis falls within the guidelines of the Steering Committee of the International
Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, which cover
the statistical analysis of magnetic resonance images.
Structural imaging
The loss of grey matter was assessed by computational segmentation of high-resolution T1-weighted images
of the brain. As an adjunct to the measurement of cytokines in peripheral blood, a T2-weighted image
(along with a proton-density-weighted image as part of a dual-echo sequence) was acquired to observe
possible neuroinflammation. Furthermore, in combination with the T1 image, we also used multichannel
texture analysis, pioneered in the assessment of multiple sclerosis lesions, to identify areas of abnormal MRI
contrast associated with inflammation and to observe potential longitudinal changes.
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Functional imaging of cognition
Echo-planar images depicting blood oxygen level dependent (BOLD) contrasts during performance of the
N-back working memory task26,27 show engagement of an executive function network comprising the
dorsolateral prefrontal cortex, the anterior cingulate cortex and the parietal cortex. Impaired functioning
in this system has been strongly implicated in the pathogenesis of schizophrenia for several decades.28
Evidence suggests that underlying deficits in intrinsic NMDA glutamate–gamma-aminobutyric acid (GABA)
neurotransmission29 and impaired connectivity between elements of the network30 contribute to the
impairment. Performance and fMRI measures in the N-back task should therefore be especially sensitive to
any NMDA cognitive-enhancing effects of minocycline, particularly in schizophrenia. BOLD-sensitive data
were also acquired while participants were resting (i.e. task absent) in order to investigate the endogenous
dynamics and functional connectivity in frontotemporal circuits widely implicated in schizophrenia.30
Objectives
Research questions
If minocycline is started early in schizophrenia, does it improve negative symptoms or lessen their development
over the next 12 months more than it does in established illnesses, and does this improve quality of life?
Does minocycline work by its neuroprotective or anti-inflammatory actions or by its effects on glutamate?
Primary and subsidiary effectiveness predictions
l Prediction 1: minocycline minimises later negative symptoms when administered during the acute phase
of psychosis, compared with standard care alone.
l Prediction 2: minocycline reduces weight gain and adverse metabolic changes associated with standard
antipsychotic treatments.
l Prediction 3: improvements in negative symptoms will translate into improved functioning and quality
of life.
Mechanistic hypotheses
Hypothesis 1: minocycline works by lessening a degenerative process that is most active in the acute phase
of psychosis and is responsible for the development of negative symptoms. The hypothesis predicts that
the loss of grey matter, known to occur during the early years following the onset of psychosis, will be
lessened by minocycline treatment and that this will correlate with, and explain, improved negative symptoms.
Hypothesis 2: minocycline works by lessening an inflammatory process in the brain that gives rise to negative
symptoms, possibly but not necessarily mediated by subtle neurodegeneration (see hypothesis 1). The
hypothesis predicts that circulating proinflammatory cytokines will be lessened by minocycline treatment.
Hypothesis 3: minocycline works by ameliorating defective NMDA glutamate receptor function, which
mediates negative symptoms. The hypothesis predicts that minocycline will improve cortical function
as measured by fMRI activation during a working memory task and resting state connectivity, and reduce
baseline concentrations of glutamate/glutamine, as measured by magnetic resonance spectroscopy. It also
predicts that the benefits to negative symptoms wane when the drug is stopped. However, it is possible
that glutamate actions could also be neuroprotective (see hypothesis 1) whether or not minocycline
enhances glutamate function in the short term.
Some of the results of the BeneMin study have been published.31
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Chapter 2 Methods
Research design
This was a six-centre, double-blind, randomised, placebo-controlled efficacy and mechanistic study of
minocycline added to standard APD treatment compared with standard APD treatment plus placebo for
1 year, in patients in an acute episode of psychosis within 3 years of their first episode of psychosis. It rapidly
proved unrealistic to find and consent participants meeting the 3-year duration of illness criterion. The
criterion was relaxed to 5 years within the first 3 months of trial recruitment through a substantial protocol
amendment. Recruitment was carried out in association with the relevant local clinical research networks
(CRNs) of the National Institute for Health Research (NIHR) and the Scottish Mental Health Research
Network. Project RAs, with the assistance of the local CRN clinical studies officers (CSOs), recruited and
assessed patients in collaboration with local clinical teams and staff. The trial research manager organised
training of RAs and CSOs in the various assessments, and inter-reliability was recorded through rating
reference videos.
Patients were recruited while symptomatic within 5 years of onset, when an inflammatory or other
neurotoxic process may be active and susceptible to the various actions of minocycline. Consenting
patients who met the inclusion criteria were randomised to receive minocycline or matching placebo for
1 year, which was added to standard treatment and organised by the clinical team. The progress of
negative and other symptoms was monitored at intervals throughout the year in parallel with a set of
cytokine and imaging biomarkers and measures of social functioning. The stability of any changes after
treatment was stopped was assessed 3 months after the end of the trial period.
The trial was monitored and managed by the principal investigators (PIs) and the research manager using the
ethical, secure, research governance-compliant and comprehensive project management procedures established
by PsyGrid for the multicentre study of first-episode psychosis. These procedures were co-ordinated and
automated using OpenCDMS software, one of the major deliverables of PsyGrid. The OpenCDMS organises
the online or offline collection of data into a secure database, prompts for assessment, quality control and
anonymisation of data, and randomisation of treatment allocation.
In this study, patients were allocated to a treatment group according to a randomised permuted blocks
algorithm, after stratification by centre, as specified by the trial statistician. An experienced clinical trial
pharmacist oversaw the blinding and unblinding procedures. Blinded supplies of placebo and active
minocycline were manufactured and distributed to local pharmacies by Catalent (www.catalent.com).
Compliance was assessed at interview by the CSO/RA or the health-care team at their monthly contacts
and by pill counts by the pharmacies if bottles were returned.
The mechanistic biomarkers probed specific hypotheses about how minocycline works to reduce negative
symptoms and whether or not and how this is translated into improved social functioning.
A trial executive committee met weekly, chaired by the chief investigator. The trial was overseen by an
independent Trial Steering Committee (TSC) and included a patient/service user representative. They
received reports from the Data Monitoring Committee to determine whether there was evidence of
(1) harm to participants from active medication, (2) harm from withholding an overwhelmingly beneficial
treatment from those taking placebo, or (3) it being otherwise ethical or feasible to continue the trial in its
current or modified form to achieve the stated objectives.
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Participants
Inclusion criteria
l Male or female aged 16–35 years.
l Meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV),32 criteria
for schizophrenia or schizophreniform or schizo-affective psychosis as assessed by the research team.
l In an episode as defined by the presence of positive symptoms (scoring > 2 on items P1, 2, 3 or 6).
l In contact with early-intervention, community or inpatient services.
l Within 5 years of onset of symptoms.
l Intelligence quotient (IQ) of > 70.
l Male and female patients, and their partners, who were willing to use effective birth control, as defined
in the patient information leaflet (PIL), throughout the study and for 7 days after stopping trial medication.
Women had to have a negative pregnancy test.
l Able to understand and willing to give written informed consent.
l Fluent in English.
Exclusion criteria
l Current substance misuse diagnosis that in the opinion of the investigator may interfere with the study.
l Patients who, in the investigator’s judgement, pose a current serious suicidal or violence risk.
l Use of antibiotics of the tetracycline type within 2 months of baseline visit, or a history of sensitivity
or intolerance.
l History of systemic lupus erythematosus or a history of it in a first-degree relative.
l Use of any investigational drug within 30 days of baseline visit.
l Relevant current or past haematological, hepatic, renal, neurological or other medical disorder that in
the opinion of the PI/responsible medical officer (RMO) may interfere with the study.
l Taking medical treatments that could seriously interact with minocycline as described in the summary of
product characteristics (SmPC) and judged by the PI/RMO.
l Clinically significant deviation from the reference range in clinical laboratory test results as judged by
the investigator.
l Previous randomisation in the present study.
l Pregnancy or breastfeeding.
l Meeting the MRI scanning exclusion criteria (Manchester pro forma or equivalent).
Study withdrawal criteria
l The patient withdraws consent for any or no reason.
l Any adverse event (AE) considered to be related to active trial medication that is a threat to health or
well-being, as determined by the local PI, the RMO or the patient.
l At the wish of the RMO.
l Safety reasons as judged by the PI, particularly if the patient becomes pregnant.
l Worsening of psychosis considered by the local PI, the RMO or the patient to be related to active trial
medication.
l The patient is unable to comply with the restrictions on the use of concomitant medications listed
in the SmPC.
l The patient is unable to tolerate the study medication.
Research assistant interview training and procedural standardisation
Detailed standardised operating procedures and checklists were drawn up for all ratings and procedures.
The research team held 2-day meetings three times per year for harmonisation and problem-solving.
Team teleconferences were held every 1–2 weeks. The main focus was conducting standardised SCI-PANSS
interviews. Raters were trained and tested on the use of SCI-PANSS and how to make PANSS ratings using
video recordings and group discussions. RAs scored PANSS negative symptoms on up to 11 different video
METHODS
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recordings throughout the study to maintain consistency and inter-rater agreement. Agreement among the
seven principal RAs of negative scores in up to 11 reference videos of SCI-PANSS interviews produced an
intraclass correlation of 0.7.
Visits and schedule of assessments (Table 1)
Recruitment
Recruitment followed the procedures of PsyGrid. The RMO or another member of the clinical care team
who knew the patient made the first approach. The local CRN CSOs had clinical research contracts with
the CRN trusts, and they assisted with ascertaining suitable patients. Records were not accessed or screened
by researchers until consent had been obtained. The RMO assessed diagnostic and other eligibility criteria
using a checklist (Diagnostic and Eligibility Checklist) and invited potentially eligible patients to take part,
at which stage patients received the PIL. The PIL included the information that travel expenses would be
paid, and that their time and effort in attending each scanning session would be compensated with a
£30 payment. The CSO/RA arranged a screening visit if patients wanted to participate. The CSO/RA logged
the contact into a form on OpenCDMS, which allocated a patient identification number.
Screening visit
The RA obtained informed consent, having verified that the patient understood the PIL and what was
involved in the study. Consent covered case-note review and the procedures in the PIL. Separate consent
was obtained for gifting DNA for future genotyping studies in fully anonymised form to the University of
Manchester. The CSO/RA applied a diagnostic checklist to the case notes on the basis of a Mini-International
Nueropsychiatric Interview (MINI),33 reached a consensus diagnosis with the RMO and confirmed the
presence of psychotic symptoms (scoring > 2 on items for hallucinations, delusions or suspiciousness). Blood
was taken for renal and liver function tests. The participant undertook the IQ tests, and the CSO/RA tested
the participants’ urine for drugs and for pregnancy in female participants.
The RA arranged the randomisation/scanning visit, having reviewed the screening investigations. The RAs
ensured that the case report form checklist for the visit was complete and then logged the data into
OpenCDMS.
Randomisation visit
This covered baseline ratings and up to 45 minutes of scanning. Participants could stop scanning at any
time without withdrawing from the study. These activities could be spread over more than 1 day. The RAs
checked consent to continue and completed the items listed. Saliva was collected using the Oragene®-DNA
OG-500 kit (DNA Genotek Inc., Ottawa, Canada), which was posted to the neuroscience and psychiatry unit.
The patient attended their local scanner unit for a 45-minute scan. The RA, together with a radiographer,
controlled the computer projection of the N-back task and recording of performance.
The RA informed OpenCDMS that the patient should be randomised. OpenCDMS then (1) allocated the
patient to a treatment arm, (2) e-mailed the local pharmacy about which treatment ‘kit’ to use to dispense
3 months’ supply and (3) recorded when a kit was dispensed. Medication was collected by the RA.
Two-, 6- and 9-month visits
Table 1 gives a list of assessments. The RA received e-mail prompts for these visits from OpenCDMS.
A second urine dipstick test for drugs of abuse was carried out at 6 months and reported to the local PI if
positive.
Twelve-month final trial visit
During this visit, the screening visit safety measures and subsequent effectiveness measures were recapped.
At all visits the patients’ cumulative clinical drug treatment was updated from the case notes. The MINI was
repeated to ascertain diagnostic status. The scanning session was repeated. Trial medication was stopped.
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TABLE 1 Schedule of assessments
Assessment
Who When
CSO RA RMO team Screening Randomisation Month 2 Month 6 Month 9 Month 12 Post-trial follow-up
Case note diagnosis checklist ✗ ✗ ✗
Diagnostic and eligibility checklist ✗ ✗ ✗ ✗
DUP ✗ ✗
MINI for psychosis ✗ ✗ ✗
Drug treatment history ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Body weight and BMI ✗ ✗ ✗ ✗ ✗
Blood pressure and heart rate ✗ ✗ ✗ ✗ ✗
Laboratory screen ✗ ✗ ✗ ✗ ✗
Drug screen (urine) ✗ ✗ ✗ ✗
Drug use questionnaire ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Pregnancy screen (urine) ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Inclusion criteria ✗ ✗ ✗ ✗
Exclusion criteria ✗ ✗ ✗ ✗
Withdrawal criteria ✗ ✗ ✗ ✗ ✗ ✗
Consent ✗ ✗ ✗ ✗
Consent genetic ✗ ✗ ✗ ✗
Saliva Oragene kit ✗ ✗
Blood cytokine screen ✗ ✗ ✗ ✗ ✗ ✗
PANSS ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
GAF ✗ ✗ ✗ ✗ ✗ ✗ ✗
Social Functioning Scale ✗ ✗ ✗ ✗ ✗ ✗
WAIS III (current IQ) ✗ ✗ ✗ ✗ ✗
WTAR (IQ decline) ✗ ✗ ✗
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Assessment
Who When
CSO RA RMO team Screening Randomisation Month 2 Month 6 Month 9 Month 12 Post-trial follow-up
Other cognitive tasks ✗ ✗ ✗ ✗ ✗
EPS scales ✗ ✗ ✗ ✗ ✗
Calgary Depression Scale for Schizophrenia ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
ANNSERS (side effects) ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
7-point compliance scale ✗ ✗ ✗ ✗ ✗
MRI screening questionnaire ✗ ✗ ✗
MRI scanning ✗ ✗ ✗
ANNSERS, Antipsychotic Non-Neurological Side Effects Rating Scale; BMI, body mass index; EPS, extrapyramidal symptoms; GAF, Global Assessment of Functioning; WAIS, Wechsler Adult
Intelligence Scale; WTAR, Wechsler Test of Adult Reading.
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Fifteen-month follow-up visit
Safety and efficacy measures were repeated.
Interventions
Study medication and blinding
Minocycline (modified release) or matching placebo was taken as two 100-mg capsules per day for
2 weeks (the standard clinical dose), and increased to three 100-mg capsules per day for the remainder
of the 12-month study period, added to standard APD therapy and routine care. A dose of 300 mg per
day was selected to maximise exposure without increasing side effects.34 Because it is a modified-release
preparation, the capsules can be taken once, twice or three times per day to a maximum of three capsules
in 24 hours, as preferred. Catalent Pharma Solutions (Somerset, NJ, USA) manufactured matching placebo
and minocycline capsules, carried out quality control and assays as required by the Medicines and Healthcare
products Regulatory Agency and carried out labelling and distribution of supplies to trust pharmacies.
Assessments
Primary clinical outcome variable
1. Negative symptom severity as defined by negative symptom subscale score on the PANSS. This is the
gold standard for comprehensively rating symptoms of schizophrenia. The negative symptom subscale is
composed of seven items, each rated 1–7.35
Secondary clinical outcome variables
1. Full-scale PANSS and positive syndrome subscale score.
2. Calgary Depression Scale for Schizophrenia (CDSS) (self-rating).
3. Functional outcome:
¢ Global Assessment of Functioning (GAF) from DSM-IV32
¢ Social Functioning Scale (SFS) self-rating in seven domains.36
Primary biomarker outcome variables
1. Medial prefrontal grey matter volume (GMV) (H1).
2. Circulating cytokine IL-6 concentration (H2).
3. Dorsolateral prefrontal cortex BOLD response, percentage correct and connectivity during the N-back
task (H3).
4. Cognitive outcomes:
¢ Blyler Wechsler Adult Intelligence Scale (WAIS)III short form – current IQ37
¢ IQ decline from premorbid IQ [Wechsler Test of Adult Reading (WTAR)], which predicts later
negative symptoms37,38
¢ Digit–symbol test – processing speed39
¢ Verbal fluency – cognitive correlate of negative symptoms40
¢ Auditory Verbal Learning Task – verbal learning.41
5. Body weight and body mass index (BMI).
6. APD treatment in chlorpromazine equivalents.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
10
Secondary biomarker outcome variables
1. Change in total and other regional GMV (H1).
2. Change in cytokine screen concentrations (H2).
3. Change in resting connectivity (H3).
Side effects and comorbidity
1. Substance misuse: urine drug screens.
2. Extrapyramidal symptoms (EPS):
¢ the Simpson and Angus scale for pseudo-Parkinsonian symptoms and signs42
¢ the Barnes Akathisia scale43
¢ the Abnormal Involuntary Movement Scale (AIMS) for tardive dyskinesia.44
3. APD subjective side effects: Antipsychotic Non-Neurological Side Effects Rating Scale
(ANNSERS), developed in CUtLASS (Cost Utility of the Latest Antipsychotic drugs in Schizophrenia Study)
and used in PsyGrid.45
4. Seven-point treatment adherence scale.46
5. Plasma minocycline concentration at 6 and 12 months.
Cytokine function
At the initial screen, a blood sample was collected into ethylenediaminetetraacetic acid (EDTA), and subaliquots
of plasma were prepared for measurement of inflammatory markers. All markers were analysed at the King’s
College London centre. Cytokines were measured using Meso Scale Discovery (MSD) (Rockville, MD, USA)
V-PLEX sandwich immunoassays in accordance with the manufacturer’s instructions. MSD Proinflammatory
Panel 1 (human) kits were used for the measurement of IL-1RA, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13,
tumour necrosis factor alpha and interferon alpha. Patient blood samples were added to individual wells,
together with a solution containing detection antibodies conjugated with electrochemiluminescent labels
(‘sulfo-tag’, a MSD trademark). Eight standards (or ‘calibrators’) were created. All samples were measured
in duplicate. With a few exceptions, all samples from the same patient were analysed together in the same
plate. Each pair of plates (proinflammatory panel/customised cytokine panel) was analysed together so that
the full range of analytes were measured in each patient sample in one session. High and low controls were
used to assess variance between plates. The interassay coefficient of variations was < 10%. High-sensitivity
C-reactive protein (hsCRP) and IL-1RA were measured at the Clinical Biochemistry Laboratory at King’s
College Hospital. Further blood samples were collected at 6 and 12 months to evaluate treatment effects
on inflammation and then again at 15 months to determine whether or not the impact had been sustained.
Exploratory analyses of the relationship between changes in cytokine concentration and the effects of
minocycline on clinical outcomes and on structural and functional imaging biomarkers were carried out.
Plans to measure gene expression for cytokines in blood were not implemented.
Oragene kits were stored in the neuroscience and psychiatry unit; however, too few patients consented to
donate DNA to make genotyping worthwhile.
Minocycline assay for compliance
After the end of the study, and with a minor amendment, spare plasma samples from the 6- and 12-month
cytokine samples were assayed for minocycline. Only samples from the group allocated to minocycline were
assayed, together with a few from the placebo group. Assays were carried out in the laboratory of Professor
Nicholas Barnes at the University of Birmingham. On the day of analysis, patient serum was thawed and mixed
with perchloric acid (Sigma-Aldrich, St Louis, MO, USA) to a final concentration of 0.2M, to precipitate protein,
which was removed by centrifugation (17,200 revolutions per minute for 5 minutes). Sample supernatant
was transferred into autosampler vials (Thermo Scientific™ Chromacol™, Thermo Fisher Scientific, Waltham,
MA, USA) for assay by high-performance liquid chromatography (HPLC)-ultraviolet/visible detection.
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The HPLC system was a Dionex UltiMate™ 3000 RSLCnano UHPLC system with an automatic Rheodyne™
injector (Dionex Corporation, Sunnyvale, CA, USA) (130-µl fixed loop; 50-µl injection volume). Samples were
separated using a Luna® 5 µm C18 LC column (Phenomenex, Torrance, CA) using a mobile phase consisting
of 25 mM KH2PO4 (pH 2.85) with 10% acetonitrile delivered at a flow rate of 1.0 ml per minute. After
generation of a minocycline calibration curve, samples were run in batches of six before a positive control
was run (20 µg/ml minocycline standard). Minocycline levels were quantified using a MWP-3000 RS diode
array detector (UltiMate™ DAD-3000; ThermoFisher Scientific, Waltham, MA, USA) at a wavelength of
350 nm. The data were analysed by Thermo Fisher Scientific (Waltham, MA, USA) Dionex Chromeleon
software to integrate peaks and calculate minocycline levels by referring to the calibration curve.
Assessment of safety
Screening and follow-up safety assessments
The clinical team and RAs confirmed the absence of symptoms and signs using a checklist and the recorded
sitting blood pressure and heart rate. Blood samples were taken for haematology and differential white-cell
count, and for clinical chemistry, to confirm normal renal and liver function. These assessments were repeated
after 12 months in the trial or at the time of withdrawal from the study. The RAs tested urine for pregnancy
in females (about 40% of the sample) with a dipstick test. This was repeated at each follow-up until the end
of the treatment phase. In the event of a positive test, the patient was withdrawn from the investigational
medicinal product and the general practitioner was informed. The participant was followed up for safety
reporting to the conclusion of the pregnancy. AE reporting and procedures were followed (see protocol on the
project web page: URL: www.journalslibrary.nihr.ac.uk/programmes/eme/0910023/#/; accessed 14 June 2019).
Sample size
The study was completed in 12 English and Scottish trusts, associated with six academic centres, each
with a PI, a RA and an imaging centre. The chief investigator and research manager at the University of
Manchester managed the trial. The academic centres had previously collaborated in the PsyGrid and
NeuroPsyGrid consortia,25 which included four of the six imaging centres that had produced harmonised
procedures through their involvement with the NeuroPsyGrid consortium. The sample size was derived
from recruitment rates and PANSS scores from the PsyGrid study.
The study was designed to produce clinical and biomarker data in 170 patients completing 1 year of either
placebo or minocycline add-on treatment (85 patients per group). This sample size has 90% power to
detect a standardised effect size of 0.5 in the primary clinical outcome (e.g. a group difference in negative
symptom scores of 3 units, assuming that the within-group standard deviation is equal to 6 units – as estimated
from the Manchester-led MRI trial and PsyGrid clinical data) using a two-tailed t-test at a p-value of < 0.05.
A difference of 3 units is the smallest effect that we would consider to have any clinical significance.
A simple t-test produces a conservative estimate. Power was greater in practice using a repeated measures
design and conditioning on relevant baseline covariates. For statistical reasons we chose not to base our
sample size calculations on mediator variables or on their hypothesised relationship with the primary outcome.
However, based on the NeuroPsyGrid data collected from five research centres, the minimal detectable
difference in grey matter is 2% at 80% probability with the sample size calculated above. This is much smaller
than the published MRI changes over 1 year.14,15
Calculations about recruitment were based on previous experience with the PsyGrid CRN consortium and
our previous minocycline study. In the Chaudhry et al. study2 in Pakistan and Brazil, 25% of those assessed
were randomised and 29% of patients dropped out during the trial to an equal extent in both arms. We
assumed a 25% dropout rate both from screening and from randomisation onwards. These figures were
intended to be pessimistic. It was anticipated that dropout rates might be lower in the UK than in Pakistan
and Brazil because of the more developed clinical care system and the involvement of patients and patient
organisations in the design and monitoring of the study. The assumed dropout rates gave figures of 282
METHODS
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participants at screening and 226 participants at randomisation to produce completion in 170 participants.
Each recruitment centre therefore needed to screen 2.1 patients per month and randomise 1.7 patients per
month. These figures were achieved by several centres in the PsyGrid study. The RA workload was realistic
at a rate of one combined MRI scanning and clinical rating session per week and one or two clinical
follow-up ratings per week.
Imaging analysis
Derivation of primary and secondary mechanistic variables
Almost all procedures and tasks for MRI assessment were those implemented in the NeuroPsyGrid
collaboration. MRI assessments were undertaken by patients at baseline and 12 months, and were analysed
to test the mechanistic hypotheses. Differences between treatment arms and associations with outcome
variables were tested both in a hypothesis-driven approach by focusing on a priori regions of interest,
defined by an anatomical atlas, and in an exploratory manner at all intracerebral locations (i.e. whole brain).
T1-weighted high-resolution MRI images were acquired, from which estimates of the distribution of GMV
were made using standard voxel-based morphometry. All images were registered in a standard anatomical
space of the Montreal Neurological Institute template to facilitate between-subject analyses. Additionally,
T2-weighted and proton density images were acquired with a dual-echo sequence, which, together with the
T1 data, were used to identify areas of abnormal MRI contrast associated with inflammation in a whole-brain
examination. Mean GMV was extracted from the medial prefrontal cortex for each patient (H1), as well as
across the whole brain.
Echo-planar images depicting BOLD functional contrast were acquired during performance of the N-back
working memory task, which engages an executive function network. BOLD-sensitive data were also
acquired while participants were resting (i.e. without externally applied stimuli) to investigate endogenous
dynamics and functional connectivity.
BOLD-sensitive data sets were initially pre-processed to correct for patient head movement. Root-mean-
square head deviations were estimated for each participant across the acquired volumes to estimate
residual head motion. At each intracerebral voxel, a general linear model was regressed onto the BOLD
time series to estimate orthogonal contrasts of stimuli of the working memory task, namely 1-back and
2-back versus 0-back, and 1-back versus 2-back. The patterns of brain activation associated with the
contrasts were estimated from the baseline data of all patients. Mean BOLD responses were extracted from
regions of interest defined by the anatomical atlas and corresponding to significantly activated regions,
namely the dorsolateral prefrontal cortex (H3). Mean reaction time and accuracy of response to task stimuli
were also recorded.
Statistical testing of regions of interest imaging data (functional or structure) used similar statistical models to
those used for clinical outcome measures, comprising a main effect of treatment, a main effect of time and
a treatment-by-time interaction, along with covariates for centre, age and sex. Effects of treatment were
identified by significant treatment-by-time interactions, which were further investigated for the direction of
the effect by appropriate post hoc testing. These models were also adopted for testing behavioural measures
during the working memory task as well as at each intracerebral voxel in whole-brain testing of imaging
measures. To control for type I errors due to multiple comparisons, and to account for non-independent
values in neighbouring voxels, robust, well-validated methods of non-parametric inference on spatially
extended regions were used.
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Data analysis
Overview
The statistical analysis was overseen by study statistician, PI Graham Dunn. A draft statistical analysis plan
was submitted to the TSC for approval as part of its 9-month assessment (see Report Supplementary
Material 1). There were no interim analyses, and all analyses were carried out after the collection of the
final outcome measures. All statistical analyses of the clinical, cognitive and biomarker outcomes were
analysed using Stata® version 14 (StataCorp LP, College Station, TX, USA).
Summary statistics
Tables of summary statistics were generated for all primary and secondary outcomes and for selected
baseline variables. These were inspected for preliminary evidence of treatment effects. Baseline variables
were used to check the baseline balance of the randomised arm.
Treatment effect estimation
Treatment effects were reported using 95% confidence intervals (CIs), supplemented by their associated
p-values. An effect was regarded as statistically significant if the p-value was ≤ 0.05, which was reduced
to 0.01 when treatment effects at each of the four follow-up times were evaluated separately.
Note that the treatment effect is essentially the average outcome for the treated arm minus the average
outcome for the placebo arm. So for a severity score (high is a poor outcome), a beneficial effect of
minocycline would be indicated by a treatment effect estimate that is negative (i.e. below zero). For a
function score (high is a good outcome), a beneficial effect would be indicated by a treatment effect
estimate that is positive (i.e. above zero).
Primary clinical outcome
Treatment effects on severity of negative symptoms were estimated through the use of a random-effects
regression model (using Stata’s xtreg command) after allowing for time of follow-up (2, 6, 9 or 12 months:
treated as a categorical variable), centre and baseline (pre-randomisation) severity of negative symptoms.
The effect of time of follow-up on treatment efficacy is evaluated by the treatment-by-time interactions
and treatment effects at the four follow-up times, estimated accordingly. When there was no significant
variation in the treatment effect over time (i.e. no treatment-by-time interaction), the interaction was
dropped from the model and treatment efficacy common to all four follow-up times was estimated. All
models contained centre-by-time and baseline severity-by-time interactions. Sensitivity of efficacy estimates
for the effects of poor compliance with medication and other covariates on loss to follow-up was assessed
through descriptive summary statistics and the use of inverse probability weighting as described below.
Secondary clinical outcomes
Similar methods to those used for the primary clinical outcomes were also used here, using mixed-effects
models involving data from 2-, 6-, 9- and 12-month follow-up, or, where appropriate, using data collected
at 6 and 12 months. For variables that were collected only at 12-month follow-up, a simple analysis of
covariance (ANCOVA) model was employed, specifying treatment centre and corresponding baseline value
of the outcome as covariates.
Primary biomarker outcome variables
Grey matter volume was measured at baseline and 12 months only, so a simple ANCOVA model was
employed, specifying treatment centre and corresponding baseline value as covariates. IL-6 and hs-CRP,
being measured at two follow-up times, were analysed in the same way as were negative symptoms.
Allowing for missing outcome data: construction of inverse probability weights
Treatment effect estimates may be sensitive to assumptions concerning mechanisms of attrition. An obvious
candidate as a predictor of attrition is the level of compliance with allocated medication. Unfortunately, only
87% (180 out of 207) of the trial participants provided data on their levels of compliance (see Results) at
METHODS
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one or more of the follow-up assessments, and it was therefore decided that this component of the trial
analysis should be relatively informal; it is reported in Appendix 2. Rather than look at the full data set,
the analyses were limited to looking at the effects of minocycline on negative symptom scores, the primary
outcome variable only, at the 12-month follow-up assessment.
To investigate patterns of attrition, a logistic regression model was used to explore which baseline
characteristics, together with treatment allocation and patterns of adherence to allocated treatment,
predicted which participants provided negative symptom outcome data at 12 months after randomisation
(separately for each randomised arm). If deemed necessary, the final models were used to generate an
expected probability of providing outcome data (for each arm separately), and the reciprocal of this
estimated probabilit was used as an inverse probability weight for use in the random-effects models for
the primary outcome.
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Chapter 3 Results
Participant recruitment
Route to recruitment
Patients were recruited from community mental health teams in a variety of ways from site to site and trust
to trust. RAs kept in contact with their local community mental health teams. They reviewed the current
caseloads with care co-ordinators or medical staff, and they attended outpatient clinics. The CSOs from
the local NIHR Clinical Research Network teams were briefed about the study at site initiation visits and
throughout the study. Generally, community mental health teams and CSO staff made initial contact with
potential patients to request permission for RAs to approach them about the study and to talk through
the PIL. The number of patients considered potentially eligible varied widely because in some centres
computerised lists of patients were available. Altogether, 2227 patients were considered for inclusion and
572 received PIL visits. After 24 hours, 267 consented to be screened for inclusion and were allocated an
identification number by OpenCDMS. A total of 229 patients attended a screening assessment, of whom
10 failed to meet the inclusion criteria, five did not consent to continue and four withdrew. A total of 207
patients were successfully randomised and allocated to a treatment code and pharmacy pack: 104 were
assigned to receive minocycline and 103 were assigned to receive placebo.
Flow through the study
The Consolidated Standards of Reporting Trials (CONSORT) flow diagram (Figure 1) shows the numbers of
participants remaining in the study, including those who missed an assessment but attended a subsequent
one, up to and including the 12-month visit: the end of the treatment phase. The number of participants
seen at each appointment for whom ratings were recorded is also shown. Overall, 78 out of 207 (38%)
of the randomised participants dropped out during the 12-month treatment phase. The great majority
(63/78, 81%) of the reasons were either participant’s request or loss to follow-up. In terms of the primary
outcome measure at 6 months, scores were available for 66% of those randomised and, at 12 months,
61%. The numbers of participants dropping out were identical (39 on placebo and 39 on minocycline)
and 33 and 3, respectively, withdrew and were lost to follow-up.
Table 2 shows the assignment to study treatment across the 12 allocation centres, each of which had a
collaborating trust pharmacy, linked to Open CDMS, and the six universities of the PIs and RAs. It can
be seen that each centre allocated a similar number of participants to placebo and minocycline. Each
pharmacy and trust required a site initiation visit, so there were varying delays before centres were open
for recruitment.
The course of recruitment in each centre is shown Figure 2. The first pharmacy was ready to dispense in
London in December 2012, but the first patient was not randomised until 16 April 2013. The 207th
patient was randomised in May 2015 and the last 12-month visit was on 9 September 2016. A steady
randomisation rate of 11 per month was achieved throughout 2014 (see Figure 2). In October 2013,
recruitment was lagging behind the target rate of 225 participants, with 172 completing the 12 months
of the study. With the approval of the Efficacy and Mechanism Evaluation programme, the target was
reduced to 207 on the grounds that retention was better than expected, and a new collaborating centre
with a new PI, Rachel Upthegrove, was initiated, together with a new recruiting centre, the Cheshire Wirral
Partnership. These new centres recruited at a rapid rate, and, together with improved recruitment in other
centres, 207 participants had been recruited by May 2015 (Figure 3).
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Baseline characteristics and matching
The two treatment groups did not differ materially in terms of age, sex or any baseline measures of the
primary and other major outcome variables (Table 3). Mean total PANSS scores of 67 (placebo group) and
69 (minocycline) indicated a mild to moderate level of severity,47 and this is corroborated by GAF scores in
the mid-50s, indicating a moderate level of severity of symptoms or impairment of social and occupational
function. The mean CDSS score was > 5 in both treatment groups, and scores of > 6 are associated with
meeting diagnostic criteria for a major depressive episode. In both groups, premorbid IQ as assessed with
Candidates for inclusion
(n = 2227)
PIL
(n = 572)
Consent and ID number
(n = 267)
Screened
(n = 229)
Randomisation
(n = 207)
• Clinical exclusions,
   n = 10
• Patient w/d, n = 5
• No consent, n = 5
• Unknown, n = 2
• In study, n = 88
• PANSS, n = 85
• In study, n = 74
• PANSS, n = 67
• In study, n = 77
• PANSS, n = 69
Month 2
Month 6
• In study, n = 70
• PANSS, n = 62
Month 9
• In study, n = 71
• PANSS, n = 68
Month 9
• In study, n = 65
• PANSS, n = 65
Month 12
• In study, n = 48
• PANSS, n = 48
15-month f/u 15-month f/u
• In study, n = 41
• PANSS, n = 41
• In study, n = 64
• PANSS, n = 62
Month 12
Month 6
Month 2
• In study, n = 88
• PANSS, n = 83
• Patient w/d, n = 4
• LTFU, n = 6
• Moved, n = 1
• Skin, n = 1
• Dysphagia, n = 2
• Malaise, n = 1
• Patient w/d, n = 5
• LTFU, n = 9
• Moved, n = 1
• Abdominal pain, n = 1
• Patient w/d, n = 3
• LTFU, n = 7
• Malaise, n = 2
• Mole, n = 1
• Vomit, n = 1
• Patient w/d, n = 1
• LTFU, n = 4
• Patient w/d, n = 2
• LTFU, n = 15
• LTFU, n = 4
• Patient w/d, n = 3
• LTFU, n = 7
• Abdominal pain, n = 1
• Patient w/d, n = 2
• LTFU, n = 3
• Relapse, n = 1
• Patient w/d, n = 2
• LTFU, n = 3
• Visual dist, n = 1
• Epilepsy, n = 1
• Patient w/d, n = 5
• LTFU, n = 18
Trial medications cease
Placebo Minocycline
• In study, n = 104
• PANSS, n = 104
• In study, n = 103
• PANSS, n = 103
FIGURE 1 The CONSORT flow diagram. f/u, follow-up; ID, identification; LTFU, lost to follow-up; w/d, withdrawn.
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TABLE 2 Treatment allocation by centre
Allocation pharmacies Placebo (n) Minocycline (n) Total (N)
University of Manchester
Royal Manchester Children’s Hospital 24 21 45
Meadowbrook Unit, Salford Royal Hospital 6 11 17
Royal Blackburn Hospital 24 24 48
University of Birmingham
Birmingham and Solihull Mental Health NHS Foundation Trust 10 9 19
University of Cambridge
Fulbourn Hospital, Cambridge 10 9 19
Cavell Centre, Peterborough 4 5 9
University of Edinburgh
Royal Edinburgh Hospital 7 8 15
King’s College London
Maudsley Hospital, London 7 6 13
University College London
St Bernard’s Hospital, Londona 4 5 9
St Charles Hospital, Londona 4 4 8
Whittington Hospital, Londona 3 0 3
St Anne’s Hospital, Londona 1 1 2
Total 104 103 207
a Combined to form a single centre for the purpose of the analyses of efficacy.
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FIGURE 3 Course of recruitment by centre. Vertical axis shows the cumulative number of participants recruited.
CWP, Cheshire Wirral Partnership; KCL, King’s College London; UCL, University College London.
TABLE 3 Baseline demographics and outcome variables
Measure
Placebo (male, n= 73;
female, N= 30)
Minocycline (male, n= 77;
female, N= 27)
n Mean SD n Mean SD
Age 101 25.7 5.1 103 25.5 5.2
Negative symptoms (PANSS) 104 16.8 5.5 103 17.7 5.9
Positive symptoms (PANSS) 104 17.3 5.3 103 16.3 4.1
Total PANSS score 103 69.3 15.4 103 67.1 13.2
CDSS score 103 5.5 5.0 103 5.2 4.3
GAF score 103 56.2 11.6 102 55.5 9.1
Weight (kg) 101 86.8 25.3 97 82.6 19.6
BMI (kg/m2) 101 28.7 7.6 96 27.1 6.2
Processing speed 91 52.8 16.8 95 58.0 16.7
Current IQ 100 89.2 15.9 101 91.2 14.0
Premorbid IQ 98 95.4 19.8 100 97.7 1.7
GMV, left (ml) 88 5.7 0.8 94 5.6 0.7
GMV, right (ml) 88 4.6 0.7 94 4.6 5.8
N-back 1 + 2 > 0-back (%BOLD) 88 0.12 1.25 94 –0.02 1.48
Cytokine IL-6 (pg/ml) 100 0.84 0.64 101 0.69 0.46
hsCRP (mg/l) 100 3.83 5.45 101 3.08 3.82
SD, standard deviation.
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the WTAR was just below 100, whereas current IQ was about 5 points lower. Thirteen participants had
raised hsCRP levels (> 10 mg/l) at baseline, indicating a likely recent viral or possibly bacterial infection.
Overview of minocycline effects
Minocycline had no discernible influence on any outcome variable in terms of direction, magnitude or
statistical significance. The treatment effects common to all follow-ups are summarised in Table 4, and
none achieved statistical significance. Treatment effects are the difference in group means (minocycline
minus placebo) attributable to treatment after controlling for baseline and centre, as described in the
analysis plan. Treatment effects with negative signs indicate lower scores in the minocycline group than
in the placebo group. Thus, negative treatment effects for severity variables indicate a beneficial effect
of minocycline, whereas for functional scores, positive treatment effects indicate a beneficial effect of
minocycline. There is no consistent tendency for beneficial effects with minocycline across the outcome
measures. Because there are no statistically significant effects, statistical analyses are presented only for
primary outcomes; other analyses are presented in Appendix 1.
TABLE 4 Summary of best estimates of treatment effects
Primary outcome Estimate SE p-value 95% CI
Negative symptomsa –0.19 0.53 0.73 –1.23 to 0.85
Clinical outcomes
Positive symptomsa –0.19 0.47 0.68 –1.12 to 0.73
Total symptoms (PANSS)a –0.58 1.62 0.72 –3.75 to 2.59
CDSS scorea –0.06 0.40 0.88 –0.84 to 0.72
GAF scorea 2.71 2.15 0.21 –1.57 to 6.98
SFS withdrawalb –0.24 0.40 0.55 –1.03 to 0.55
SFS relationsb –0.02 0.27 0.94 –0.55 to 0.51
SFS independence-performanceb –0.78 0.89 0.38 –2.53 to 0.97
SFS recreationb –0.91 0.89 0.30 –2.65 to 0.82
SFS prosocialb 0.19 1.24 0.88 –2.25 to 2.62
SFS independence-competenceb –0.49 0.67 0.46 –1.79 to 0.81
SFS employmentb –0.12 0.43 0.78 –0.95 to 0.71
Processing speedc –2.14 2.26 0.35 –6.63 to 2.35
Current IQc –0.56 1.53 0.72 –3.59 to 2.47
Weightc 2.71 2.15 0.21 –1.57 to 6.98
Biomarker outcomes
GMV (left)c –0.09 0.11 0.40 –0.30 to 0.12
GMV (right)c –0.07 0.07 0.34 –0.21 to 0.08
N-back 1 + 2 > 0-back (%BOLD)c –0.66 0.43 0.13 –1.53 to 0.20
IL-6b 0.07 0.10 0.46 –0.12 to 0.26
hsCRPb 1.72 1.60 0.28 –1.42 to 4.85
SE, standard error.
a 2-, 6-, 9- and 12-month follow-up.
b 6- and 12-month follow-up.
c 12-month follow-up.
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Primary clinical outcome measure
Negative symptom subscale score
The minimum possible negative score is 7 and the maximum is 49. Scores decreased by slightly less than
3 points over the trial (Table 5). There are no significant treatment effects (Tables 6–8). Negative scores
calculated from items N1 + N2 + N3 + N4 + N6 +G7 +G16 according to Marder et al.48 produced very
similar means, correlating > 0.9 at each time point with the standard negative score. There is no indication
of a rebound worsening after cessation of treatment at 12 months (see Table 5).
Analysis for scores and other fixed models are systematically presented in the same way for each of the
outcomes: (1) estimates of relevant model parameters (see Table 6), (2) estimates of treatment effects at
the available follow-up times (see Table 7) and (3) estimate of treatment effects, assuming that there is no
variation in the treatment effects across the different follow-up times (see Table 8).
TABLE 5 The PANSS negative symptom subscale scores with (minimum–maximum) range
Measure
Placebo Minocycline
n Mean SD n Mean SD
Negative (7–49)
Baseline 104 16.8 5.5 103 17.7 5.9
2 months 85 15.1 5.8 83 16.4 5.6
6 months 67 15.7 5.8 69 15.8 6.5
9 months 62 14.5 4.9 68 15.9 6.3
12 months 65 14.2 5.2 62 16.4 6.2
Follow-up 48 14.0 4.9 41 15.6 6.6
SD, standard deviation.
TABLE 7 Negative symptom subscale: estimated treatment effects at each follow-up time (derived from linear
combinations of the above parameter estimates)
Follow-up Estimate SE p-value 95% CI
TE 2 months 0.303 0.672 0.653 –1.015 to 1.621
TE 6 months –1.449 0.746 0.052 –2.910 to 0.012
TE 9 months –0.223 0.768 0.772 –1.728 to 1.282
TE 12 months 0.465 0.777 0.549 –1.057 to 1.988
SE, standard error; TE, treatment effect.
TABLE 6 Negative symptom subscale: estimates of relevant mixed-model parameters
Parameter Estimate SE p-value 95% CI
TE 2 months 0.303 0.672 0.653 –1.015 to 1.621
TE 6 months – TE 2 monthsa –1.752 0.799 0.028 –3.318 to –0.186
TE 9 months – TE 2 monthsa –0.525 0.819 0.521 –2.130 to 1.080
TE 12 months – TE 2 monthsa 0.163 0.826 0.844 –1.456 to 1.781
SE, standard error; TE, treatment effect.
a Differences between treatment effects (i.e. treatment by follow-up time interaction).
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Secondary clinical outcome measures
Positive symptom subscale and total scale scores
Total scores at baseline of about 70 correspond to a mild to moderate overall severity of illness,47 and this
is concordant with the GAF scores in Table 9. Mean scores improved in both groups to a similar extent
(see Table 9).
Calgary Depression Scale for Schizophrenia (self-rating)
The mean CDSS scores of > 5 predict depression diagnosis with a sensitivity of 88% and a specificity of
69%.49 This indicates a high prevalence of depressive symptoms. Although scores improve in both groups,
this may reflect dropout of those with greater depressive symptoms (Table 10).
Global Assessment of Functioning
This measure rates whichever is the more severe of impaired social function and symptoms severity, with
lower values indicating the greater impairment. The mean values lie in the 50–60 range, which represents
a moderate level of symptoms or social impairment. Small improvements in mean GAF score occurred in both
groups, although these were slightly greater in the placebo group than in the minocycline group (Table 11).
TABLE 8 Negative symptom subscale: estimated treatment effect common to all follow-up times
TE Estimate SE p-value 95% CI
Common TE –0.186 0.530 0.726 –1.225 to 0.854
SE, standard error; TE, treatment effect.
TABLE 9 The PANSS positive symptom subscale and total score
Measure
Placebo Minocycline
n Mean SD n Mean SD
Positive (range 7–49)
Baseline 104 17.3 5.3 103 16.3 4.1
2 months 86 14.5 4.8 83 13.8 4.5
6 months 67 14.4 5.2 69 13.4 5.0
9 months 63 13.6 5.0 68 12.8 4.6
12 months 65 14.0 4.8 63 13.4 6.1
Follow-up 48 13.8 5.2 41 13.2 5.3
Total (range 32–210)
Baseline 103 69.3 15.4 103 67.1 13.2
2 months 85 60.1 15.7 83 59.6 14.9
6 months 66 59.4 16.8 69 57.5 15.7
9 months 62 56.8 14.7 68 57.0 14.7
12 months 65 57.1 17.3 62 59.0 17.3
Follow-up 48 55.8 15.4 41 57.7 16.5
SD, standard deviation.
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Social Functioning Scale
Greater scores indicate better social function, but there were no group differences, and the scores did not
change over the course of the study (Table 12).
Cognitive performance
Cognitive scores tended to improve equally in both groups (Table 13).
Body weight and body mass index
Increases in BMI and body weight occurred with both placebo and minocycline, but there were no
statistically significant differences between the treatment groups (Table 14).
Antipsychotic drug treatment
Drug treatments at baseline and at 12 months were grouped into main classes and each class was expressed
as a percentage of the total number of drugs prescribed. There were no clear group differences in the
pattern of treatment current at baseline or at 12 months. Almost all patients were taking second-generation
(‘atypical’) antipsychotics rather than first-generation medications. Many patients in both groups were
taking antidepressants at both times (Figure 4).
TABLE 10 Calgary Depression Scale for Schizophrenia
Time
Placebo Minocycline
n Mean SD n Mean SD
Baseline 103 5.50 4.96 103 5.17 4.27
2 months 95 3.40 3.99 94 3.31 3.85
6 months 83 3.05 4.17 83 2.60 3.59
9 months 80 2.73 3.77 79 3.25 3.78
12 months 78 3.12 4.28 76 3.09 3.98
Follow-up 66 2.88 4.43 57 2.49 3.53
SD, standard deviation.
TABLE 11 Global Assessment of Functioning score
Measure
Placebo Minocycline
n Mean SD n Mean SD
GAF (range 0–100)
Baseline 103 56.2 11.6 102 55.5 9.1
2 months 85 59.5 11.4 83 58.1 11.6
6 months 65 59.6 12.1 68 60.2 13.2
9 months 63 60.8 12.0 67 58.5 12.7
12 months 64 60.4 13.4 60 56.3 14.1
Follow-up 47 61.7 13.0 41 56.5 13.6
SD, standard deviation.
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TABLE 12 Social Functioning Scale subscale scores
Measure
Placebo Minocycline
n Mean SD n Mean SD
SFS1: social engagement/withdrawal (range 0–15)
Baseline 101 10.2 2.9 103 10.5 3.1
6 months 65 11.0 3.2 65 11.0 3.2
12 months 63 10.9 3.4 61 10.7 3.7
Follow-up 48 11.5 3.5 41 10.6 3.2
SFS2: interpersonal behaviour/relations (range 0–9)
Baseline 102 6.6 1.9 103 6.4 1.8
6 months 65 7.2 2.0 65 6.8 2.0
12 months 63 7.1 2.0 61 6.6 2.2
Follow-up 48 7.1 2.0 41 6.9 2.1
SFS3: independence-performance (range 0–39)
Baseline 102 26.1 6.4 103 26.3 7.5
6 months 65 27.4 7.2 65 26.7 8.2
12 months 63 27.4 7.0 61 26.3 6.8
Follow-up 48 26.6 6.8 41 26.0 7.4
SFS4: recreation (range 0–45)
Baseline 102 17.7 6.01 103 18.2 7.8
6 months 65 18.4 7.8 65 17.6 7.3
12 months 63 18.4 7.0 61 17.4 7.1
Follow-up 48 17.1 6.8 41 17.4 7.6
SFS5: prosocial activities (range 0–69)
Baseline 102 16.7 10.5 103 16.6 10.3
6 months 65 17.3 11.6 65 16.3 9.6
12 months 63 17.2 10.8 61 16.5 10.1
Follow-up 48 18.9 11.5 41 15.9 10.0
SFS6: independence-competence (range 0–39)
Baseline 102 34.0 6.2 103 34.8 4.9
6 months 65 35.0 4.8 65 34.7 5.4
12 months 63 34.8 5.0 61 34.0 5.1
Follow-up 48 35.5 3.9 41 34.0 7.1
SFS7: employment/occupation (range 0–10)
Baseline 102 4.9 3.0 103 4.7 3.1
6 months 65 5.6 3.4 64 4.9 3.3
12 months 63 5.9 3.1 61 5.3 3.3
Follow-up 47 5.3 3.3 41 5.4 3.7
SD, standard deviation.
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The most common oral antipsychotics used did not differ at baseline, and nor did the average daily dose,
expressed in olanzapine equivalents (Table 15).
The groups were well matched with regard to oral antipsychotics, with olanzapine being the most
frequent. The mean daily doses in olanzapine equivalents (mg/day) were closely similar (see Table 15).
Few participants were on depot/long-acting injection antipsychotic medication; the most common were
paliperidone and its parent compound, risperidone (Table 16). The groups were well matched with regard
to long-acting injections. ‘Clozapine’ was recorded as the depot name in three cases. This may have been
a confusion with clopixol.
Primary biomarker outcome measures
Grey matter volume
There were no systematic trends in GMV over time and no treatment effects (Tables 17 and 18).
TABLE 14 Body weight and BMI
Measure
Placebo Minocycline
n Mean SD n Mean SD
Weight (kg)
Baseline 101 86.8 25.3 97 82.6 19.6
12 months 58 91.8 28.5 53 88.0 18.2
BMI (kg/m2)
Baseline 101 28.7 7.6 96 27.1 6.2
12 months 58 30.1 8.5 53 28.7 5.5
SD, standard deviation.
TABLE 13 Main cognitive scores
Measure
Placebo Minocycline
n Mean SD n Mean SD
Processing speed
Baseline 91 52.8 16.8 95 58.0 16.7
12 months 59 58.2 15.8 58 56.1 16.2
Follow-up 47 61.2 15.9 36 62.6 16.2
Current IQ
Baseline 100 89.2 15.9 101 91.2 14.0
12 months 61 94.6 16.6 59 93.7 14.2
Follow-up 49 97.0 17.5 38 98.2 16.1
SD, standard deviation.
RESULTS
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TABLE 16 Depot/long-acting injection antipsychotic medications at baseline and 12 months
Depot drug
Baseline 12 months
Placebo Minocycline Placebo Minocycline
Paliperidone 4 5 2 3
Risperdal Consta® 2 1 2 1
Flupentixol 3 3 2 1
Clopixol® 1
Clozapine 1 1 1
Aripiprazole 1 1
Pipotiazine 1 1
Zuclopenthixol 1 1
Olanzapine 1
Total 13 12 7 8
TABLE 15 Common oral antipsychotics at baseline
Oral drug
Placebo Minocycline
Count OE (mg/day) Count OE (mg/day)
Olanzapine 25 11.58 34 12.05
Aripriprazole 15 8.14 19 9.96
Quetiapine 18 9.07 13 10.10
Risperidone 15 5.83 8 5.83
Clozapine 6 10.20 6 7.95
Amisulpride 7 13.75 10 9.38
Total (mean) 86 (9.76) 90 (9.21)
OE, olanzapine equivalents.
TABLE 17 Medial prefrontal GMV (mm3) by treatment
Measure
Placebo Minocycline
n Mean SD n Mean SD
GMV left
Baseline 88 5669 786 94 5644 723
12 months 54 5509 787 45 5593 70
GMV right
Baseline 88 4581 658 94 4574 583
12 months 54 4425 680 45 4543 551
SD, standard deviation.
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Circulating interleukin 6 and high-sensitive C-reactive protein concentrations
There were no systematic trends in cytokine concentrations over time and no treatment effects (Tables 19–22).
N-back performance and functional magnetic resonance imaging blood oxygen
level-dependent response in dorsolateral prefrontal cortex
There were no statistically significant treatment effects on performance or on fMRI BOLD responses during
the N-back task (see analysis in Deakin et al.31 and Report Supplementary Material 1).
TABLE 18 Estimated treatment effects for GMV
Parameter Estimate SE p-value 95% CI
GMV left
TE 12 months –91.196 106.867 0.396 –303.828 to 121.437
GMV right
TE 12 months –69.106 72.180 0.341 –212.722 to 74.510
SE, standard error; TE, treatment effect.
TABLE 20 Cytokine IL-6: estimates of relevant mixed-model parameters
TE Estimate SE p-value 95% CI
6 months 0.026 0.133 0.843 –0.233 to 0.286
12 months 0.125 0.143 0.382 –0.155 to 0.405
SE, standard error; TE, treatment effect.
TABLE 19 Circulating cytokine concentrations
Time point
Placebo Minocycline
n Mean SD n Mean SD
IL-6
Baseline 100 0.840 0.639 101 0.690 0.458
6 months 65 0.902 0.754 57 0.843 0.926
12 months 56 0.811 0.623 53 0.793 0.570
hsCRP
Baseline 100 3.83 5.45 101 3.08 3.82
6 months 65 5.33 9.54 57 4.56 11.23
12 months 56 4.40 5.30 51 6.01 18.91
SD, standard deviation.
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Secondary biomarker outcome variables
Total and other regional grey matter volumes
Cytokine screen
Resting state connectivity
In view of the lack of therapeutic effect of minocycline, the secondary mechanistic biomarkers have not
been analysed at present.
Side effects and comorbidity
Substance misuse
There were more cannabis-positive urine tests in the placebo group at baseline and 6 months than in the
minocycline group (Table 23). Confining an exploratory analysis to those with cannabis-free urine did
not reveal a treatment-responsive group.
TABLE 21 Cytokine IL-6: estimated TEs at each follow-up time (derived from linear combinations of the parameter
estimates in Table 20)
Parameter Estimate SE p-value 95% CI
TE 6 months 0.026 0.133 0.843 –0.233 to 0.286
TE 12 months – TE 6 monthsa 0.099 0.195 0.613 –0.283 to 0.481
SE, standard error; TE, treatment effect.
a Differences between TEs (i.e. treatment by follow-up time interaction).
TABLE 22 Cytokine IL-6: estimated treatment effect common to all follow-up times
TE Estimate SE p-value 95% CI
Common TE 0.072 0.097 0.458 –0.118 to 0.262
SE, standard error; TE, treatment effect.
TABLE 23 Number of positive urine drug-screen results and substances identified
Screening Month 6
Placebo Minocycline Placebo Minocycline
Sample size 102 102 67 67
Positive drug test 39 22 21 10
Opiates 6 4 0 2
Cannabis 27 11 19 5
Barbiturates 6 6 2 3
Amfetamine 4 3 1 2
Other: benzodiazepines 7 5 0 2
Other: cocaine 3 2 0 1
RESULTS
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Extrapyramidal symptoms side effect summaries
The prevalence of EPS side effects was low and there were no group differences (Tables 24–26).
Non-neurological side-effect scores were minimal and did not differ between the groups (Table 27).
TABLE 24 Parkinsonism: mean EPS side effects scale total scores
Time point n Mean SD Min. Max.
Placebo
Baseline 102 1.60 2.42 0 15
6 months 66 1.29 2.01 0 10
12 months 61 1.25 2.59 0 13
Follow-up 47 1.04 2.27 0 13
Minocycline
Baseline 101 1.60 2.42 0 13
6 months 65 1.60 2.07 0 7
12 months 61 1.72 2.46 0 10
Follow-up 41 1.83 2.52 0 9
Max., maximum; min., minimum; SD, standard deviation.
TABLE 25 Akathisia: distribution of Barnes Akathisia Rating Scale global item scores
Group
Score
n0 1 2 3
Baseline
Placebo 83 7 12 1 103
Minocycline 77 13 9 1 100
12 months
Placebo 51 3 9 0 63
Minocycline 49 6 4 1 60
TABLE 26 Tardive dyskinesia: distribution AIMS total scores
Group
Score
n0 1 2 3 4 5
Baseline
Placebo 89 9 1 2 0 0 103
Minocycline 86 8 1 1 0 3 100
12 months
Placebo 58 2 3 0 0 0 63
Minocycline 54 2 2 0 0 1 60
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Seven-point treatment adherence scale
Adherence scores were bimodally distributed (Table 28); most participants rated their adherence maximally,
but the percentage of scores of < 3 (%) increased to 23–25% by 12 months.
There were no group differences in the distribution of adherence scores in Table 28. Analysis of the effect
of treatment on subscales in participants with maximal self-rated adherence (score of 7) did not reveal a
statistically significant benefit or a trend towards a benefit of minocycline on the primary or secondary
symptom ratings (results not shown).
Low treatment adherence scores at 2 months predicted approximately 80% non-completion (i.e. dropout)
at 12 months, and this was equally true in both treatment arms (Table 29). The data formed part of the
sensitivity analysis reported in Appendix 2.
TABLE 27 Antipsychotic Non-Neurological Side-Effects Rating Scale
Time point
Placebo Minocycline
n Mean SD n Mean SD
Baseline 103 13.36 7.09 102 11.49 7.30
2 months 80 7.62 6.96 80 6.39 5.97
6 months 59 6.75 6.92 67 6.57 5.90
9 months 58 6.10 6.19 62 6.70 6.06
12 months 60 6.90 6.62 58 7.29 6.77
Follow-up 44 5.51 5.96 38 6.70 7.34
SD, standard deviation.
TABLE 28 Distribution of total adherence scores from 1 (poor) to 7 (excellent)
Allocation
Number with adherence score
< 3 (%) > 5 (%)1 2 3 4 5 6 7
2 months
Placebo 5 2 0 1 4 9 68 8 87
Minocycline 8 0 0 1 0 7 72 9 90
6 months
Placebo 7 1 1 1 5 8 47 11 79
Minocycline 5 1 1 2 3 8 51 8 83
9 months
Placebo 8 3 2 2 4 7 42 16 72
Minocycline 10 4 0 0 1 6 48 20 78
12 months
Placebo 14 3 2 2 3 4 41 25 65
Minocycline 11 4 0 0 1 3 46 23 75
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Plasma minocycline concentrations at 6 and 12 months
Minocycline was assayed in 56 blood samples from the minocycline group. It was detectable in 32 (57%)
at 6 months and 35% at 12 months (Table 30). Analysis of the effect of treatment on subscales in the
32 participants with detectable minocycline levels compared with the placebo group did not reveal a
statistically significant or trend towards benefit of minocycline (results not shown).
Adverse events and serious adverse events
Adverse events and reactions
Sixty-seven AEs were reported for participants in the placebo group and 60 were reported in the minocycline
group in the per-protocol reporting period between randomisation and 15-month follow-up (Table 31).
They occurred in 14 MedDRA system organ class categories (www.meddra.org/), with few marked differences
in frequency. The most common MedDRA categories were gastrointestinal (category 7; n = 31), psychiatric
(category 19; n = 24), neurological (mostly headache; category 7; n = 24) and dermatological (category 23;
n = 18) (see Table 29). Worsening of psychiatric illness was twice as common in the placebo group as in the
minocycline group (16 compared with 8 of the 207 total randomised). Eleven adverse reactions (i.e. AEs
that are judged possibly related to trial medication) occurred in the placebo group and five occurred in the
minocycline, consisting of skin rash, headache and gastrointestinal upset.
TABLE 29 Association between medication adherence scores at 2 months and missing negative symptom subscale
scores at 12 months
Adherence score Non-missing (%) Missing (%)
Placebo
< 6 2 (15.38) 11 (84.62)
6–7 63 (81.82) 14 (18.18)
Missing 0 (0) 14 (100)
Minocycline
< 6 2 (20.00) 8 (80.00)
6–7 60 (75.00) 20 (25.00)
Missing 0 (0) 13 (100)
TABLE 30 Plasma minocycline concentration
Measure 6 months 12 months
Completed visit (n) 67 69
Blood taken 56 52
< Limit of detection 24 34
Detectable minocycline 32 18
% detectable 57 35
Range 0.17–6.35 0.14–3.48
Mean 1.112 1.173
Standard deviation 1.29 0.99
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Serious adverse events
Hospitalisations were more common in the minocycline group (n = 18) than in the placebo group (n = 11)
(Table 32). There were 15 admissions in 10 minocycline-treated patients, and 10 admissions in six placebo-
treated patients. The admissions were due to worsening of psychiatric illness, with a combination of
intensification of psychosis, dysphoria and suicidal ideation and intent. None was rated by the local PIs as
a reaction to trial medication or as a suspected unexpected serious adverse reaction; other factors were
noted, such as poor adherence to medication and alcohol and substance misuse.
TABLE 31 Non-serious AEs by MedDRA category
MedDRA category System Placebo Minocycline
2 Cardiac disorders 5 1
3 Congenital, familial and genetic disorders 0 1
4 Ear and labyrinth disorders 1 0
5 Endocrine disorders 1 2
7 Gastrointestinal disorders 12 19
10 Immune system disorders 0 1
11 Infections and infestations 9 2
14 Metabolism and nutrition disorders 0 1
15 Musculoskeletal and connective tissue disorders 3 3
17 Nervous system disorders 8 12
19 Psychiatric disorders 16 8
20 Renal and urinary disorders 1 1
22 Respiratory, thoracic and mediastinal disorders 1 1
23 Skin and subcutaneous tissue disorders 10 8
Total 67 60
TABLE 32 All AEs by treatment allocation and MedDRA class
Event type Placebo Minocycline
AEs
Total number of AEsa 67 60
Psychiatric events (MedDRA category 19)b 16 8
ARs
Rash 3 2
Gastrointestinal upset 6 2
Headache 2 1
Total number of ARs 11 5
SAEs
Total number of SAEs 11 18
Psychiatric hospitalisation events (patients) 10 (6) 15 (10)
Admission for abdominal pain (patients) 0 (0) 3 (2)
Deep-vein thrombosis 1 0
AR, adverse reaction; SAE, severe adverse event.
a AE occurring per protocol between randomisation and 15-month follow-up visit or 60 weeks if they left the study before
follow-up. Any other events known to us are reported in the text.
b MedDRA category 19 is the psychiatric category for AEs. In all cases here, a mix of suicidal intent and intensifications of
symptoms occurred. They were classified as SAEs if hospitalisation occurred.
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No deaths occurred during the trial. Two deaths occurred after completion of the minocycline group.
One patient died of an overdose 9 months after their 12-month study visit. Another developed a deep-vein
thrombosis and died of a pulmonary embolus 2 months after the follow-up visit (5 months after the end
of trial treatment). Although this event occurred outside the reporting period, a thorough search of the
literature and web resources was made, and no cases of deep-vein thrombosis or pulmonary embolus
associated with minocycline use have been described. The patient was prescribed clozapine and was a
smoker, both of which are known to be predisposing factors.
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Chapter 4 Discussion
Limitations
There are number of potential limitations of the BeneMin study. The aim of the study was to determine
whether or not minocycline protects against the development of negative symptoms over 1 year. The
design involved a compromise between, on the one hand, early neuroprotective treatment when a
putative neuropathic process might be most active and, on other hand, allowing sufficient time for the
process to produce negative symptoms. We chose 1 year based on our previous experience and the
evidence that observable changes in brain structure occur over 1 year in first-episode psychosis. However,
recent evidence from longitudinal studies in first-episode psychosis challenges our premise that a 1-year
follow-up would be sufficient; this indicates that negative symptoms reduce as positive symptoms stabilise
and remain low and stable for up to 2 years in those remaining in services and treatment.50 The mean
initial negative score of about 17 stabilising at 15 after 1 year in the BeneMin study is very similar to the
profile reported by Mezquida et al.50 The present baseline score of 17 is appreciably lower than that of
22 in the Pakistan study,2 and this may have diminished the possibility of finding a protective effect of
minocycline. Indeed, the greatest predictor of follow-up in BeneMin was the baseline PANSS negative score,
suggesting that influences on negative symptoms had already operated prior to the minocycline trial.
The trial had a high dropout rate, but this was mainly as a result of participant choice and was clearly not
different between the two groups. Similarly, poor treatment adherence in one or other group is a potential
source of bias, but there was no group difference in self-rated attitude to trial medication. Furthermore,
sensitivity analysis (see Appendix 2) found that treatment effects were not modified by poor compliance
and loss to follow-up. Poor adherence as well as dropout will have reduced exposure to active treatment
and thus lessened the power of the study to detect an effect on negative symptoms. However, exploratory
analyses found no evidence of trends to efficacy compared with placebo in treatment-adherent individuals
or in those with detectable minocycline in plasma at 6 or 12 months.
Poor training or reliability between raters is a potential explanation for a false-negative study. In BeneMin,
extensive training and discussions of ratings continued throughout the trial. A single RA recruited and tested
the bulk of participants in each centre because staff turnover was gratifyingly low. This would tend to
increase consistency. Agreement among the seven principal RAs of negative scores in up to 11 reference-
video SCI-PANSS interviews produced an intraclass correlation of 0.7. Centre was included as a factor in
estimating all treatment effects, but none was statistically significant. Furthermore, there were no effects
of treatment in any centre when considered separately. Because treatment effects do not vary between
centres, it seems unlikely that beneficial effects of minocycline were obscured by a marked deviation in
rating or by other unknown systematic deviations in some centres.
The lack of effect of minocycline is backed up by the lack of effect on secondary measures that are known
to relate to negative symptoms, some of which do not involve external raters; the CDSS and the SFS are
self-rated, and the latter has objective measures, such as being in employment. Performance on cognitive
function tasks is a known correlate of negative symptoms but was unaffected by minocycline. The secondary
measures changed very little over the course of the study year, as might be expected had a continuing
neuropathic process been active early in psychosis.
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Efficacy of minocycline in relation to other studies
There is no evidence from the BeneMin study that minocycline has important effects on the course of early
schizophrenia, in particular on negative symptoms. This study followed the design used in a previous
two-centre placebo-controlled RCT conducted by Chaudhry et al.,2 in which minocycline improved negative
symptoms when added to treatment as usual for 1 year. In the major centre in Pakistan (70 completers),
only negative symptoms improved compared with placebo, by about 3 points on the negative scale. In the
Brazilian centre in 24 participants, negative symptoms improved by 8 points more than in those receiving
placebo, with similar large improvements in positive subscale and total scores. None of eight other trials of
minocycline in the meta-analysis of Xiang et al.51 reported benefits on positive symptoms. There are many
possible reasons for the discrepancy between the current findings and the Chaudhry trial results concerning
psychosocial, aetiological and therapeutic differences between countries. For example, inflammatory
mechanisms might plausibly be more prevalent in Pakistan and therefore be amenable to minocycline’s
anti-inflammatory actions. Although there was no evidence for the existence of an ‘inflammatory’ subgroup
of participants with marked responses to minocycline in the Pakistan study, four participants in Brazil did
have large responses. The magnitude of the difference between BeneMin and the Pakistan trial is small and
may simply reflect chance variation.
Two other studies3,52 have reported effectiveness of minocycline in early psychosis. A study by Liu et al.52 would
appear to be an outlier given the large and widening 14-point difference on the Scale for the Assessment of
Negative Symptoms (SANS) ratings compared with placebo at 10 weeks after treatment (see meta-analysis
of Xiang et al.51). Lefkovitz et al.3 reported the emergence of negative symptoms 17 weeks after an acute
episode in their placebo-treated group, which did not occur in those randomised to minocycline throughout
the episode. These effects on SANS ratings were not apparent on PANSS ratings, in keeping with the
present study. In summary, critical examination of the limited previous literature offers little support for
substantial effects of minocycline on negative or positive symptoms early in psychosis.
It is possible that inflammation is a mechanism relevant to the pathogenesis of severe negative symptoms
and cognitive impairment in chronicity and the ‘deficit syndrome’53 or in treatment resistance. An early
case study54 reported dramatic improvement in two patients with catatonia prescribed minocycline as an
antibiotic for pneumonia, and this was followed by a 4-week open-label study5 in 22 patients with resistant
illnesses and high positive and negative PANSS scores, all of which improved after minocycline. A number
of other case reports have reported improvement in negative symptoms55–58 following the addition of
minocycline. However, only two double-blind RCTs in established schizophrenia have been published.
A study59 in patients partially responding to clozapine reported no effect on negative symptoms (the primary
outcome variable) rated from the Brief Psychiatric Rating Scale (BPRS), but some differences in other BPRS
scores were reported, with improvement in cognitive performance. A study from Iran60 reported very large
benefits on negative symptoms in patients with chronic illnesses.
Mechanistic markers
The most direct evidence for neuroinflammation in early schizophrenia has come from PET imaging of microglial
activation. Various radioligands have been developed that have affinity for the 18-kDa translocator protein
(TSPO) in the mitochondria of activated microglia in order to image neuroinflammation. Two early studies in
schizophrenia reported increased 11C-PK11195 binding in small groups of 10 and 7 patients compared with
controls.20,61 However, seven later studies in larger samples using PK11195 and more recently developed ligands
did not report increases; this includes four studies in recent-onset schizophrenia.62–65 Only two studies have
studied drug-naive patients on antipsychotic medication. Holmes et al.62 found no increases in PK11195 binding
in untreated first-episode patients but increases in those on risperidone. There were no relationships with
circulating hsCRP concentrations. Collste et al.65 found markedly reduced 11C-PBR28 binding in several brain
regions in drug-naive recently diagnosed patients. One recent study66 stands out as it reported increases in
11C-PBR28 binding in both people at ultra-high risk and those in a first episode. The findings are controversial
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
38
because when analysed using conventional modelling (without co-varying whole-brain binding), no increases
in radioligand binding were seen. Further studies are under way but, because several reasonably powered
studies have found no increases in TSPO binding in recent-onset schizophrenia, it is questionable whether
microglial activation occurs. This in turn suggests that the lack of effect of minocycline in the BeneMin study
may reflect an absence of neuroinflammation in recent-onset schizophrenia.
Peripheral circulating cytokine concentrations were not markedly increased compared with norms in the
study laboratory, but in the absence of a control group we cannot exclude a group effect. We found no
evidence in exploratory analyses that those with above median baseline hsCRP or IL-6 concentrations showed
a greater effect of minocycline than those with below median levels on PANSS subscales or on CDSS ratings.
Minocycline had no overall effect on hsCRP or IL-6 concentrations. Remarkably, in view of the widespread use
of minocycline as an anti-inflammatory drug, only one report of minocycline effects on circulating cytokines
was found in PubMed searches. In a study67 in patients with rheumatoid arthritis, IL-6 concentrations decreased
over 6 months in the minocycline treatment group but not in the placebo group, but whether or not the group
difference was statistically significant was not clear; hsCRP decreases correlated with IL-6 decreases in the
minocycline group. A recent meta-analysis68 found no evidence that APD treatment moderated the increase
in hsCRP associated with the diagnosis of schizophrenia. It would therefore appear that the lack of effect of
minocycline on cytokines in the BeneMin study may be further evidence of a lack of peripheral inflammation in
the BeneMin participants.
Previous evidence, including from BeneMin investigators, reported raised IL-6 and interferon gamma in
patients measured within days of first presentation and in those who did not respond 3 months later.69
Few of the BeneMin sample would be non-responders judging by the mild to moderate range of total
PANSS scores. However, cytokine concentrations in the 21 participants with greatest baseline PANSS total
scores (84–118) did not differ from the remaining 180. Nevertheless, the possibility remains that peripheral
inflammation occurs during acute-phase psychosis and in association with treatment resistance, and that
anti-inflammatory drugs such as minocycline might benefit participants in these subgroups with clear
biomarker evidence of central nervous system or systemic inflammation.
Minocycline has many properties apart from its anti-inflammatory actions that should promote cell survival,
such as the antioxidant, antiapoptotic, blockade of glutamate neurotoxicity and mitochondrial damage,
which has been reviewed in two studies.17,70 Indeed, these properties were the rationale for the minocycline
study: to trial a neuroprotective agent in early schizophrenia. So far, however, minocycline’s neuroprotective
properties in preclinical assays have not been translated into clinical efficacy. It is clearly not effective in motor
neurone disease10 or multisystem atrophy.71 A possible benefit in slowing progression of multiple sclerosis has
been reported after 6 months but not 12 months of treatment.72 There are equivocal findings in a few case
reports and in pilot studies in Parkinson’s disease,71 stroke8,73 and fragile X syndrome.74 In the BeneMin
study there was no statistically significant loss of medial prefrontal GMV over the course of the study year
and, therefore, no detectable neuropathic process for minocycline to exert a neuroprotective effect. In the
Brazilian arm (n = 30) of the Chaudhry et al.2 trial, Chaves et al.75 carried out structural MRI (1.5 T) scans at
the 12-month assessment. The placebo group showed localised reductions in GMV in the left motor cortex
(BA6) and the left mid-posterior cingulate cortex (BA24) compared with the minocycline group. In the
absence of baseline scans it is not possible to know if loss of GMV occurred in the placebo group and,
therefore, whether or not the difference at 12 months represents a possible localised neuroprotective effect
of minocycline. In the BeneMin structural MRI scans, there were no effects of minocycline in any region in an
exploratory whole-brain analysis.
Any suggestion that the present study missed microglial activation because PET TSPO binding does not
detect it or that minocycline is ineffective against it would be premature in the light of recent studies in
depression. Two studies76,77 reported increased PET TSPO binding in patients with major depressive disorder,
and a further two studies78,79 reported that minocycline substantially reduced depression in treatment-resistant
patients78 and in a sample of patients with bipolar depression.79 This suggests that fundamental differences
may exist between the immune basis of psychosis and that of depression.
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Implications for research
The BeneMin study, taken together with the existing literature, suggests that up to 12 months of treatment
with minocycline does not improve the symptomatic or functional status of people within 5 years of a
diagnosis of schizophrenia. Furthermore, we found little evidence of persisting neurodegeneration or systemic
inflammation that the known actions of minocycline could target. It is possible that such processes occur in
acute-phase schizophrenia or in treatment-resistant subgroups. However, much firmer biomarker evidence
of these pathological processes would seem necessary before further trials of minocycline are carried out in
psychosis.
We suggest some priorities for future research as follows:
1. Search for other immune mechanisms in psychosis including T-cell-mediated autoimmune processes
that act via neuromodulation rather than neurodegeneration.
2. Find better radioligands for PET imaging of microglia and other inflammatory cells in the brain,
including astroglia.
3. Use novel trial designs to detect the benefit of monoclonal antibodies and other immune suppressants
in acute or treatment-resistant illnesses. This approach is encouraged by unpublished evidence
(Professor IB Chaudhry, University of Manchester and Pakistan Institute of Living and Learning, 2016,
personal communication) from a clinical trial80 that low-dose methotrexate has unexpected antipsychotic
effects.
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Appendix 1 Secondary outcomes: estimated
treatment effects
Positive and Negative Syndrome Scale positive symptom subscale score
TABLE 33 The PANSS positive mixed-model parameters
Parameter Estimate SE p-value 95% CI
TE 2 months 0.134 0.613 0.826 –1.067 to 1.336
TE 6 months – TE 2 monthsa –0.467 0.741 0.529 –1.920 to 0.986
TE 9 months – TE 2 montha –0.521 0.753 0.489 –1.998 to 0.956
TE 12 months – TE 2 monthsa –0.518 0.758 0.495 –2.004 to 0.968
SE, standard error; TE, treatment effect.
a Differences between TEs (i.e. treatment by follow-up time interaction).
TABLE 34 The PANSS positive: estimated TEs at each follow-up time (derived from linear combinations of the
parameter estimates in Table 33)
Follow-up Estimate SE p-value 95% CI
TE 2 months 0.134 0.613 0.826 –1.067 to 1.336
TE 6 months –0.332 0.676 0.623 –1.657 to 0.992
TE 9 months –0.387 0.690 0.575 –1.738 to 0.965
TE 12 months –0.383 0.696 0.582 –1.748 to 0.982
SE, standard error; TE, treatment effect.
TABLE 35 The PANSS positive TE common to all follow-up times
TE Estimate SE p-value 95% CI
Common TE –0.194 0.471 0.680 –1.117 to 0.729
SE, standard error; TE, treatment effect.
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Positive and Negative Syndrome Scale total scale score
TABLE 36 The PANSS total score: mixed-model parameters
Parameter Estimate SE p-value 95% CI
TE 2 months 0.854 1.969 0.664 –3.004 to 4.712
TE 6 months – TE 2 monthsa –3.378 2.148 0.116 –7.588 to 0.832
TE 9 months – TE 2 monthsa –2.137 2.177 0.326 –6.405 to 2.131
TE 12 months – TE 2 monthsa –1.037 2.199 0.637 –5.346 to 3.272
SE, standard error; TE, treatment effect.
a Differences between TEs (i.e. treatment by follow-up time interaction).
TABLE 37 The PANSS total score: estimated TEs at each follow-up time
Follow-up Estimate SE p-value 95% CI
TE 2 months 0.854 1.969 0.664 –3.004 to 4.712
TE 6 months –2.524 2.152 0.241 –6.743 to 1.694
TE 9 months –1.283 2.185 0.557 –5.566 to 3.000
TE 12 months –0.183 2.210 0.934 –4.514 to 4.149
SE, standard error; TE, treatment effect.
TABLE 38 The PANSS total score: TE common to all follow-up times
TE Estimate SE p-value 95% CI
Common TE –0.580 1.615 0.720 –3.746 to 2.586
SE, standard error; TE, treatment effect.
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Global Assessment of Functioning score
TABLE 39 The GAF: mixed-model parameters
Parameter Estimate SE p-value 95% CI
TE 2 months –0.132 1.601 0.934 –3.269 to 3.005
TE 6 months – TE 2 monthsa 2.562 1.779 0.150 –0.924 to 6.048
TE 9 months – TE 2 monthsa 0.018 1.794 0.992 –3.498 to 3.533
TE 12 months – TE 2 monthsa –1.056 1.831 0.564 –4.644 to 2.532
SE, standard error; TE, treatment effect.
a Differences between TEs (i.e. treatment by follow-up time interaction).
TABLE 40 The GAF: estimated TEs at each follow-up time (derived from linear combinations of the above
parameter estimates)
Follow-up Estimate SE p-value 95% CI
TE 2 months –0.132 1.601 0.934 –3.269 to 3.005
TE 6 months 2.430 1.759 0.167 –1.018 to 5.877
TE 9 months –0.114 1.779 0.949 –3.602 to 3.373
TE 12 months –1.188 1.819 0.514 –4.753 to 2.376
SE, standard error; TE, treatment effect.
TABLE 41 The GAF: estimated TE common to all follow-up times
TE Estimate SE p-value 95% CI
Common TE 2.705 2.154 0.212 –1.570 to 6.980
SE, standard error; TE, treatment effect.
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Social Functioning Scale
Social Functioning Scale 1: social engagement/withdrawal
TABLE 42 Social engagement/withdrawal: estimates of mixed-model parameters
Parameter Estimate SE p-value 95% CI
TE 6 months –0.030 0.478 0.950 –0.967 to 0.908
TE 12 months – TE 6 monthsa –0.452 0.556 0.417 –1.541 to 0.638
SE, standard error; TE, treatment effect.
a Differences between TEs (i.e. treatment by follow-up time interaction).
TABLE 43 Social engagement/withdrawal: estimated TEs at each follow-up time (derived from linear combinations
of the parameter estimates in Table 42)
Follow-up Estimate SE p-value 95% CI
TE 6 months –0.030 0.478 0.950 –0.967 to 0.908
TE 12 months –0.482 0.502 0.337 –1.465 to 0.502
SE, standard error; TE, treatment effect.
TABLE 44 Social engagement/withdrawal: estimated TE common to all follow-up times
TE Estimate SE p-value 95% CI
Common TE –0.239 0.403 0.554 –1.029 to 0.551
SE, standard error; TE, treatment effect.
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Social Functioning Scale 2: interpersonal behaviour/relations
TABLE 45 Interpersonal behaviour/relations: estimates of mixed-model parameters
Parameter Estimate SE p-value 95% CI
TE 6 months –0.033 0.299 0.913 –0.618 to 0.553
TE 12 months – TE 6 monthsa 0.029 0.283 0.917 –0.525 to 0.584
SE, standard error; TE, treatment effect.
a Differences between TEs (i.e. treatment by follow-up time interaction).
TABLE 46 Interpersonal behaviour/relations: estimated TEs at each follow-up time (derived from linear combinations
of the parameter estimates in Table 45)
Follow-up Estimate SE p-value 95% CI
TE 6 months –0.033 0.299 0.913 –0.618 to 0.553
TE 12 months –0.003 0.309 0.992 –0.610 to 0.603
SE, standard error; TE, treatment effect.
TABLE 47 Interpersonal behaviour/relations: estimated TE common to all follow-up times
TE Estimate SE p-value 95% CI
Common TE –0.019 0.269 0.943 –0.546 to 0.507
SE, standard error; TE, treatment effect.
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Social Functioning Scale 3: independence-performance
TABLE 48 Independence-performance: estimates of mixed-model parameters
Parameter Estimate SE p-value 95% CI
TE 6 months –0.664 1.018 0.514 –2.660 to 1.331
TE 12 months – TE 6 monthsa –0.247 1.035 0.812 –2.276 to 1.782
SE, standard error; TE, treatment effect.
a Differences between TEs (i.e. treatment by follow-up time interaction).
TABLE 49 Independence-performance: estimated TEs at each follow-up time (derived from linear combinations of
the above parameter estimates)
Follow-up Estimate SE p-value 95% CI
TE 6 months –0.664 1.018 0.514 –2.660 to 1.331
TE 12 months –0.911 1.052 0.386 –2.973 to 1.151
SE, standard error; TE, treatment effect.
TABLE 50 Independence-performance: estimated TE common to all follow-up times
TE Estimate SE p-value 95% CI
Common TE –0.780 0.894 0.383 –2.533 to 0.973
SE, standard error; TE, treatment effect.
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
56
Social Functioning Scale 4: recreation
TABLE 51 Recreation: estimates of mixed-model parameters
Parameter Estimate SE p-value 95% CI
TE 6 months –0.728 1.039 0.483 –2.764 to 1.308
TE 12 months – TE 6 monthsa –0.395 1.153 0.732 –2.655 to 1.866
SE, standard error; TE, treatment effect.
a Differences between TEs (i.e. treatment by follow-up time interaction).
TABLE 52 Recreation: estimated TEs at each follow-up time (derived from linear combinations of the above
parameter estimates)
Follow-up Estimate SE p-value 95% CI
TE 6 months –0.728 1.039 0.483 –2.764 to 1.308
TE 12 months –1.123 1.078 0.297 –3.235 to 0.989
SE, standard error; TE, treatment effect.
TABLE 53 Recreation: estimated TE common to all follow-up times
TE Estimate SE p-value 95% CI
Common TE –0.914 0.886 0.302 –2.650 to 0.823
SE, standard error; TE, treatment effect.
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Social Functioning Scale 5: pro-social activities
TABLE 54 Pro-social activities: estimates of mixed-model parameters
Parameter Estimate SE p-value 95% CI
TE 6 months 0.058 1.423 0.967 –2.730 to 2.846
TE 12 months – TE 6 monthsa 0.269 1.491 0.857 –2.655 to 3.192
SE, standard error; TE, treatment effect.
a Differences between TEs (i.e. treatment by follow-up time interaction).
TABLE 55 Pro-social activities: estimated TEs at each follow-up time (derived from linear combinations of the
above parameter estimates)
Follow-up Estimate SE p-value 95% CI
TE 6 months 0.058 1.423 0.967 –2.730 to 2.846
TE 12 months 0.327 1.471 0.824 –2.557 to 3.211
SE, standard error; TE, treatment effect.
TABLE 56 Pro-social activities: estimated TE common to all follow-up times
TE Estimate SE p-value 95% CI
Common TE 0.185 1.240 0.881 –2.245 to 2.615
SE, standard error; TE, treatment effect.
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Social Functioning Scale 6: independence-competence
TABLE 57 Independence-competence: estimates of mixed-model parameters
Parameter Estimate SE p-value 95% CI
TE 6 months –0.447 0.773 0.563 –1.963 to 1.068
TE 12 months – TE 6 monthsa –0.096 0.850 0.910 –1.762 to 1.570
SE, standard error; TE, treatment effect.
a Differences between TEs (i.e. treatment by follow-up time interaction).
TABLE 58 Independence-competence: estimated TEs at each follow-up time (derived from linear combinations of
the above parameter estimates)
Follow-up Estimate SE p-value 95% CI
TE 6 months –0.447 0.773 0.563 –1.963 to 1.068
TE 12 months –0.543 0.801 0.498 –2.114 to 1.028
SE, standard error; TE, treatment effect.
TABLE 59 Independence-competence: estimated TE common to all follow-up times
TE Estimate SE p-value 95% CI
Common TE –0.490 0.665 0.462 –1.794 to 0.814
SE, standard error; TE, treatment effect.
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Social Functioning Scale 7: employment/occupation
TABLE 60 Employment/occupation: estimates of mixed-model parameters
Parameter Estimate SE p-value 95% CI
TE 6 months –0.352 0.473 0.456 –1.280 to 0.575
TE 12 months – TE 6 monthsa 0.500 0.444 0.260 –0.371 to 1.372
SE, standard error; TE, treatment effect.
a Differences between TEs (i.e. treatment by follow-up time interaction).
TABLE 62 Employment/occupation: estimated TE common to all follow-up times
TE Estimate SE p-value 95% CI
Common TE –0.118 0.425 0.780 –0.950 to 0.714
SE, standard error; TE, treatment effect.
TABLE 61 Employment/occupation: estimated TEs at each follow-up time (derived from linear combinations of the
above parameter estimates)
Follow-up Estimate SE p-value 95% CI
TE 6 months –0.352 0.473 0.456 –1.280 to 0.575
TE 12 months 0.148 0.486 0.761 –0.805 to 1.101
SE, standard error; TE, treatment effect.
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Cognitive outcome
Estimated treatment effects: processing speed scores and current intelligence quotient
Body weight (kg) at 12 months
TABLE 64 Body weight at 12 months: estimates of relevant ANCOVA parameters
Parameter Estimate SE p-value 95% CI
TE 12 months 2.705 2.154 0.212 –1.570 to 6.980
SE, standard error; TE, treatment effect.
TABLE 63 Processing speed and current IQ: estimates of relevant ANCOVA parameters
Parameter Estimate SE p-value 95% CI
Processing speed
TE 12 months –2.138 2.261 0.347 –6.628 to 2.353
Current IQ
TE 12 months –0.558 1.527 0.715 –3.585 to 2.468
SE, standard error; TE, treatment effect.
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High sensitive C-reactive protein
TABLE 65 High sensitive C-reactive protein: estimates of mixed-model parameters
Parameter Estimate SE p-value 95% CI
TE 6 months 0.157 2.175 0.942 –4.106 to 4.421
TE 12 months – TE 6 monthsa 3.385 3.207 0.291 –2.901 to 9.672
SE, standard error; TE, treatment effect.
a Differences between TEs (i.e. treatment by follow-up time interaction).
TABLE 66 High sensitive C-reactive protein: estimated TEs at each follow-up time (derived from linear combinations
of the above parameter estimates)
Follow-up Estimate SE p-value 95% CI
TE 6 months 0.157 2.175 0.942 –4.106 to 4.421
TE 12 months 3.543 2.357 0.133 –1.076 to 8.162
SE, standard error; TE, treatment effect.
TABLE 67 High sensitive C-reactive protein: estimated TE common to all follow-up times
TE Estimate SE p-value 95% CI
Common TE –0.061 0.398 0.879 –0.841 to 0.719
Common TE 1.715 1.599 0.284 –1.419 to 4.849
Common TEa –0.483 0.334 0.148 –1.139 to 0.172
SE, standard error; TE, treatment effect.
a Excluding observations with hsCRP values≥ 10.
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Calgary Depression Scale for Schizophrenia (total score)
TABLE 68 Calgary Depression Scale for Schizophrenia: estimates of mixed-model parameters
Parameter Estimate SE p-value 95% CI
TE 2 months –0.030 0.493 0.951 –0.997 to 0.936
TE 6 months – TE 2 monthsa –0.499 0.536 0.352 –1.550 to 0.552
TE 9 months – TE 2 monthsa 0.504 0.544 0.354 –0.562 to 1.570
TE 12 months – TE 2 monthsa –0.115 0.550 0.835 –1.194 to 0.964
SE, standard error; TE, treatment effect.
a Differences between TEs (i.e. treatment by follow-up time interaction).
TABLE 69 Calgary Depression Scale for Schizophrenia: estimated TEs at each follow-up time (derived from linear
combinations of the above parameter estimates)
Follow-up Estimate SE p-value 95% CI
TE 2 months –0.030 0.493 0.951 –0.997 to 0.936
TE 6 months –0.530 0.526 0.314 –1.561 to 0.502
TE 9 months 0.473 0.534 0.375 –0.573 to 1.520
TE 12 months –0.145 0.541 0.788 –1.205 to 0.914
SE, standard error; TE, treatment effect.
TABLE 70 Calgary Depression Scale for Schizophrenia: estimated TE common to all follow-up times
TE Estimate SE p-value 95% CI
Common TE –0.061 0.398 0.879 –0.841 to 0.719
SE, standard error; TE, treatment effect.
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Appendix 2 Sensitivity analysis
Sensitivity of treatment effects to association between compliance at
2 months and missing Positive and Negative Syndrome Scale negative
scores at 12 months
Table 71 shows the relationship between compliance at 2 months and attrition at 12 months, together with
the associated inverse probability weights (p-weights) to be used to adjust for any possible bias in estimated
treatment effects arising from this relationship. The fact that neither the levels of compliance nor loss to
follow-up of the scores appear to be related to treatment allocation would suggest that such biases are unlikely.
Instead of a mixed model, a simple ANCOVA model was used to estimate the effect of minocycline on the
12-month negative score after allowing for both baseline negative score and treatment centre. Note that
the original mixed model produced an estimated treatment effect of 0.465 (95% CI –1.507 to 1.988) on
the 12-month outcome. The present (unweighted) ANCOVA model using all available data produced a
comparable but less precise estimate of 0.757 (95% CI –1.038 to 2.552). Excluding those without 2-month
compliance scores from the analyses yielded an estimate of 0.732 (95% CI –1.068 to 2.532).
A weighted ANCOVA using participants with a non-missing compliance score produced the following
treatment-effect estimate: 1.031 (95% CI –0.711 to 2.774). Note that this estimate is even less precise
because the CIs are produced using a robust estimate of the treatment effect’s standard error (an implication
of the use of inverse probability weighting). If the participants with a missing compliance score are now
used by combining them with those with an assessed score of < 6 (Table 72), then the revised estimate is
now 1.167 (95% CI –0.581 to 2.915).
All of the above ANCOVAs produced a positive point but statistically non-significant estimate of the effect
of minocycline (a negative value would have been expected if the minocycline were beneficial). All four
estimates are qualitatively similar, indicating that the failure to find a beneficial effect of minocycline is
unlikely to have arisen from poor compliance and subsequent loss to follow-up.
TABLE 71 P-weights calculated using available adherence data
Adherence Non-missing (%) Missing (%) p-weight
Placebo
< 6 2 (15.38) 11 (84.62) 13/2
6–7 63 (81.82) 14 (18.18) 77/63
Missing 0 (0) 14 (100) –
Minocycline
< 6 2 (20.00) 8 (80.00) 10/2
6–7 60 (75.00) 20 (25.00) 80/60
Missing 0 (0) 13 (100) –
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TABLE 72 P-weights calculated with missing adherence scores coded as < 6
Adherence Non-missing (%) Missing (%) p-weight
Placebo
< 6 2 (7.41) 25 (92.58) 27/2
6–7 63 (81.82) 14 (18.18) 77/63
Minocycline
< 6 2 (8.70) 21 (91.30) 23/2
6–7 60 (75.00) 20 (25.00) 80/60
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